

REFINITIV

DELTA REPORT

10-Q

SGP PR M - MERCK & CO., INC.

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 2129

█ CHANGES 298

█ DELETIONS 1001

█ ADDITIONS 830

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2023** **March 31, 2024**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 1-6571

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

New Jersey

(State or other jurisdiction of incorporation)

22-1918501

(I.R.S. Employer Identification No.)

126 East Lincoln Avenue

Rahway New Jersey 07065

(Address of principal executive offices) (zip code)

(Registrant's telephone number, including area code) **(908) 740-4000**

Not Applicable

(Former name, former address and former fiscal year, if changed since last report.)

Securities Registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock (\$0.50 par value)	MRK	New York Stock Exchange
0.500% Notes due 2024	MRK 24	New York Stock Exchange
1.875% Notes due 2026	MRK/26	New York Stock Exchange
2.500% Notes due 2034	MRK/34	New York Stock Exchange
1.375% Notes due 2036	MRK 36A	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of common stock outstanding as of the close of business on **October 31, 2023** **April 30, 2024**: **2,534,023,084** **2,532,806,307**

Table of Contents

	Page No.
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements
	<u>Condensed Consolidated Statement of Income</u>
	<u>Condensed Consolidated Statement of Comprehensive Income</u>
	<u>Condensed Consolidated Balance Sheet</u>
	<u>Condensed Consolidated Statement of Cash Flows</u>
	<u>Notes to Condensed Consolidated Financial Statements</u>
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
Item 3.	<u>Quantitative and Qualitative Disclosures about Market Risk</u>
Item 4.	<u>Controls and Procedures</u>
	<u>Cautionary Factors That May Affect Future Results</u>
PART II	OTHER INFORMATION
Item 1.	<u>Legal Proceedings</u>
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>
Item 5.	<u>Other Information</u>
Item 6.	<u>Exhibits</u>
	<u>Signatures</u>

Part I - Financial Information

Item 1. Financial Statements

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Uunaudited, \$ in millions except per share amounts)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Sales	Sales	\$ 15,962	\$ 14,959	\$ 45,485
Sales				\$ 45,453
Sales				
Costs, Expenses and Other				
Costs, Expenses and Other				
Costs, Expenses and Other				
Costs, Expenses and Other				
Costs, Expenses and Other				
Cost of sales	Cost of sales	4,264	3,934	12,214
Cost of sales				13,530

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders	Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders	\$ 1.86	\$ 1.28	\$ 0.62	\$ 4.53
<hr/>					
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders					
<hr/>					

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Uaudited, \$ in millions)

		Three Months Ended September 30,		Nine Months Ended September 30,	
		2023	2022	2023	2022
Net Income Attributable to Merck & Co., Inc.	Net Income Attributable to Merck & Co., Inc.	\$ 4,745	\$ 3,248	\$ 1,591	\$ 11,502
Net Income Attributable to Merck & Co., Inc.					
Net Income Attributable to Merck & Co., Inc.					
Other Comprehensive Loss Net of Taxes:	Other Comprehensive Loss Net of Taxes:				
Net unrealized gain on derivatives, net of reclassifications		159	338	171	584
Other Comprehensive Loss Net of Taxes:					
Other Comprehensive Loss Net of Taxes:					
Net unrealized gain (loss) on derivatives, net of reclassifications					
Net unrealized gain (loss) on derivatives, net of reclassifications					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization					
Cumulative translation adjustment	Cumulative translation adjustment	(175)	(568)	(244)	(990)
Cumulative translation adjustment					
Cumulative translation adjustment					
		(16)	(416)	(148)	(314)
Comprehensive Income Attributable to Merck & Co., Inc.	Comprehensive Income Attributable to Merck & Co., Inc.	\$ 4,729	\$ 2,832	\$ 1,443	\$ 11,188
Comprehensive Income Attributable to Merck & Co., Inc.					

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 3 -

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, \$ in millions except per share amounts)

	September 30, 2023	December 31, 2022	
	March 31, 2024		March 31, 2024
Assets	Assets		December 31, 2023
Current Assets	Current Assets		
Current Assets			
Current Assets			
Cash and cash equivalents			
Cash and cash equivalents			
Cash and cash equivalents			
Cash and cash equivalents			
Short-term investments	Short-term investments	168	498
Accounts receivable (net of allowance for doubtful accounts of \$85 in 2023 and \$72 in 2022)		10,394	9,450
Inventories (excludes inventories of \$3,151 in 2023 and \$2,938 in 2022 classified in Other assets - see Note 7)		6,131	5,911
Accounts receivable (net of allowance for doubtful accounts of \$80 in 2024 and \$88 in 2023)			
Inventories (excludes inventories of \$3,413 in 2024 and \$3,348 in 2023 classified in Other assets - see Note 6)			
Other current assets	Other current assets	6,656	7,169
Total current assets	Total current assets	31,954	35,722
Investments	Investments	1,306	1,015
Property, Plant and Equipment, at cost, net of accumulated depreciation of \$18,446 in 2023 and \$17,985 in 2022		22,526	21,422

Property, Plant and Equipment, at cost, net of accumulated depreciation of \$18,620 in 2024 and \$18,266 in 2023			
Goodwill	Goodwill	21,183	21,204
Other Intangibles, Net	Other Intangibles, Net	19,199	20,269
Other Assets	Other Assets	10,559	9,528
		\$106,727	\$109,160
Liabilities and Equity	Liabilities and Equity		
Current Liabilities	Current Liabilities		
Current Liabilities			
Loans payable and current portion of long-term debt			
Loans payable and current portion of long-term debt			
Loans payable and current portion of long-term debt	Loans payable and current portion of long-term debt	\$ 887	\$ 1,946
Trade accounts payable	Trade accounts payable	3,509	4,264
Accrued and other current liabilities	Accrued and other current liabilities	14,840	14,159
Income taxes payable	Income taxes payable	1,981	1,986
Dividends payable	Dividends payable	1,877	1,884
Total current liabilities	Total current liabilities	23,094	24,239
Long-Term Debt	Long-Term Debt	33,972	28,745
Deferred Income Taxes	Deferred Income Taxes	1,018	1,795
Other Noncurrent Liabilities	Other Noncurrent Liabilities	7,343	8,323
Merck & Co., Inc. Stockholders' Equity	Merck & Co., Inc. Stockholders' Equity		
Common stock, \$0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	Common stock, \$0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	1,788	1,788
Common stock, \$0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	Common stock, \$0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023		

Common stock, \$0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023			
Other paid-in capital	Other paid-in capital	44,358	44,379
Retained earnings	Retained earnings	57,082	61,081
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(4,916)	(4,768)
		98,312	102,480
Less treasury stock, at cost: 1,041,809,729 shares in 2023 and 1,039,269,638 shares in 2022			
		57,066	56,489
		97,809	
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023			
Total Merck & Co., Inc. stockholders' equity	Total Merck & Co., Inc. stockholders' equity	41,246	45,991
Noncontrolling interests	Noncontrolling interests	54	67
Total equity	Total equity	41,300	46,058
		\$106,727	\$109,160

The accompanying notes are an integral part of this condensed consolidated financial statement.

- 4 -

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, \$ in millions)

		Nine Months Ended		Three Months Ended		2023
		September 30,		March 31,		
		2023	2022			
Cash Flows	Cash Flows					
from Operating	from Operating					
Activities	Activities					
Net income	Net income	\$ 1,603	\$ 11,508			
Net income	Net income					
Adjustments to	Adjustments to					
reconcile net	reconcile net					
income to net	income to net					
cash provided	cash provided					
by operating	by operating					
activities:	activities:					

Amortization	Amortization	1,582	1,623
Amortization			
Amortization			
Depreciation	Depreciation	1,326	1,394
Intangible asset impairment charges		13	910
(Income) loss from investments in equity securities, net		(240)	1,361
Charge for the acquisition of Prometheus Biosciences, Inc.		10,217	—
Income from investments in equity securities, net			
Charge for the acquisition of Harpoon Therapeutics, Inc.			
Charge for the acquisition of Imago BioSciences, Inc.	Charge for the acquisition of Imago BioSciences, Inc.	1,192	—
Deferred income taxes	Deferred income taxes	(968)	(1,261)
Share-based compensation	Share-based compensation	478	396
Other	Other	(94)	1,169
Net changes in assets and liabilities	Net changes in assets and liabilities	(2,349)	(2,435)
Net Cash	Net Cash		
Provided by Operating Activities	Provided by Operating Activities	12,760	14,665
Cash Flows from Investing Activities			
Capital expenditures	Capital expenditures	(2,874)	(3,239)
Capital expenditures	Capital expenditures		
Purchases of securities and other investments	Purchases of securities and other investments	(704)	(710)
Proceeds from sales of securities and other investments	Proceeds from sales of securities and other investments	1,489	709
Acquisition of Prometheus Biosciences, Inc., net of cash acquired		(10,705)	—

Acquisition of Harpoon Therapeutics, Inc., net of cash acquired			
Acquisition of Imago BioSciences, Inc., net of cash acquired	Acquisition of Imago BioSciences, Inc., net of cash acquired	(1,327)	—
Other acquisitions, net of cash acquired		—	(121)
Other	Other	(15)	149
Net Cash Used in Investing Activities	Net Cash Used in Investing Activities	(14,136)	(3,212)
Cash Flows from Financing Activities	Cash Flows from Financing Activities		
Proceeds from issuance of debt	5,939	—	
Payments on debt	Payments on debt	(1,752)	(2,250)
Payments on debt			
Payments on debt			
Dividends paid to stockholders			
Purchases of treasury stock	Purchases of treasury stock	(953)	—
Dividends paid to stockholders		(5,593)	(5,262)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	119	119
Other	Other	(325)	(172)
Net Cash Used in Financing Activities	Net Cash Used in Financing Activities	(2,565)	(7,565)
Effect of Exchange Rate	Effect of Exchange Rate		
Changes on Cash, Cash Equivalents and Restricted Cash	Changes on Cash, Cash Equivalents and Restricted Cash	(163)	(776)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash		(4,104)	3,112
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of \$79 and \$71 at January 1, 2023 and 2022, respectively, included in Other current assets)	12,773	8,167	
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of \$64 and \$134 at September 30, 2023 and 2022, respectively, included in Other current assets)	\$ 8,669	\$ 11,279	

Net Decrease in Cash, Cash Equivalents and Restricted Cash	
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of \$68 and \$79 at January 1, 2024 and 2023, respectively, included in <i>Other current assets</i>)	
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of \$92 and \$79 at March 31, 2024 and 2023, respectively, included in <i>Other current assets</i>)	

The accompanying notes are an integral part of this condensed consolidated financial statement.

- 5 -

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck's Form 10-K filed on **February 24, 2023** **February 26, 2024**.

The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Recently Adopted Issued Accounting Standards

In October 2021, the Financial Accounting Standards Board (FASB) issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company's consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.

In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The Company adopted the guidance effective July 1, 2023. There was no impact to the Company's consolidated financial statements upon adoption.

Recently Issued Accounting Standard Not Yet Adopted

In August 2023, the FASB Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The

amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.

In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses.
The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company's financial statements.

In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company's financial statements.

2. Acquisitions, Divestitures, Research Collaborations and Licensing Agreements

The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company's financial results.

2023 2024 Transactions

In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo's deruxtecan (DXd) antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). See Note 3 for additional information related to this collaboration.

In June 2023, March 2024, Merck acquired Prometheus Biosciences, Harpoon Therapeutics, Inc. (Prometheus) (Harpoon), a clinical-stage biotechnology immunotherapy company pioneering developing a precision medicine approach novel class of T-cell engagers designed to harness the power of the body's immune system to treat patients suffering from cancer and other diseases, for the discovery, development, \$765 million and commercialization also incurred \$56 million of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of \$11.0 billion included \$1.2 billion of costs to settle share-based equity awards (including \$700 million to settle unvested equity awards). Prometheus' transaction costs. Harpoon's lead candidate, MK-7240 MK-6070 (formerly PRA023) HPN328, is a humanized monoclonal antibody directed to tumor necrosis factor-like T-cell engager targeting delta-like ligand 1A, 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy in a target Phase 1/2 clinical trial in certain patients with advanced cancers associated with both intestinal inflammation and fibrosis. MK-7240 expression of DLL3. The study is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn's disease, and other autoimmune conditions. also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction was accounted for as an asset acquisition of an asset since MK-7240 accounted for MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of \$877 million, including cash of \$368 million, investments of \$296 million, deferred tax assets of \$218 million and other net liabilities of \$5 million \$165 million, as well as a charge of \$10.2 billion \$656 million to Research and development expenses in the first nine months quarter of 2023 2024 related to the transaction. There are no future contingent payments associated with the acquisition.

In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (Elanco) for \$1.3 billion in cash. The Elanco aqua business to be acquired consists of an innovative portfolio of medicines and vaccines, nutritions and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. Upon closing, the acquisition will broaden Animal Health's aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvix, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health's warm water vaccine portfolio. In addition to these products, the DNA-based vaccine

- 6 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and other customary closing conditions. The transaction will be accounted for as a business combination.

2023 Transactions

In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs antibody drug conjugates (ADCs) for the treatment of cancer.

- 6 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of \$175 million, which was recorded in as a charge to Research and development expenses in the first nine months quarter of 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating an additional candidate under the agreement. Kelun-Biotech remains eligible to receive future contingent payments aggregating up to \$725 million \$600 million in development-related payments, \$1.95 billion \$1.6 billion in regulatory milestones, and \$3.9 billion \$3.1 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all remaining candidates achieve regulatory

approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested \$100 million in Kelun-Biotech's Kelun-Biotech shares in January 2023.

In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for \$1.35 billion (including payments to settle share-based equity awards) and also incurred approximately \$60 million of transaction costs. Imago's lead candidate, bomedemstat MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. A Phase 3 clinical trial evaluating bomedemstat for the treatment of certain patients with essential thrombocythemia is underway. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of \$219 million, as well as a charge of \$1.2 billion to Research and development expenses in the first nine months quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.

2022 Transactions Spin-Off of Organon & Co.

In October 2022, connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Royalty Pharma plc (Royalty Pharma) Organon entered into a funding arrangement under series of interim operating agreements pursuant to which Royalty Pharma paid in various jurisdictions where Merck \$50 million held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to co-fund Merck's development costs for a Phase 2b trial the separation, Merck continued to market, import and distribute such products on behalf of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for Organon until such time as the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical relevant licenses and regulatory success permits transferred to Organon, with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to Research and development expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% Organon receiving all of the development costs up to \$375 million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as economic benefits and burdens of such activities. As of March 31, 2024, only one jurisdiction remains under an expense within Other (income) expense, net upon receipt of the related approvals.

In September 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a \$250 million charge to Research and development expenses in the third quarter and first nine months of 2022 interim operating agreement. Additionally, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. V940 (mRNA-4157) is currently being evaluated in combination with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma in a Phase 3 clinical trial being conducted by Moderna.

In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (circRNA) therapies, Organon entered into a collaboration agreement number of manufacturing and supply agreements (MSAs) with terms ranging from four years to discover, develop, and commercialize multiple programs, including vaccines and therapeutics ten years. The amounts included in the areas condensed consolidated statement of infectious disease income for the above MSAs include sales of \$107 million and oncology. Under \$94 million and related cost of sales of \$110 million and \$107 million for the terms first quarter of the agreement, Merck made an upfront payment to Orna of \$150 million 2024 and 2023, respectively. The amounts due from Organon for all spin-off related agreements were \$462 million and \$632 million at March 31, 2024 and December 31, 2023, which was recorded respectively, and are reflected in Research Other current assets. The amounts due to Organon under these agreements were \$193 million and development \$598 million at March 31, 2024 and December 31, 2023, respectively, and are included in expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent payments aggregating up to \$440 million in development-related payments, \$675 million in regulatory milestones, and \$2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested \$100 million in Orna's Series B preferred shares in fourth quarter of 2022.

In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion's investigational candidate ODM-208 (MK-5684) Accrued and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of \$290 million, which was recorded in current liabilitiesResearch and development expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved.

Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical

- 7 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

development of the investigational ADC. Merck made an upfront payment of \$35 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to \$82 million in developmental milestones, \$334 million in regulatory milestones, and \$485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.

In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech's trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as

a monotherapy and in combination with *Keytruda* for advanced solid tumors. Upon option exercise, Merck made a payment of \$30 million, which was recorded in *Research and development expenses* in the first nine months of 2022. Additionally, Merck agreed to make an additional payment of \$25 million upon technology transfer, which occurred in the third quarter of 2023 and will be paid in the fourth quarter of 2023. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to \$111 million to fund Kelun-Biotech's ongoing research and development activities, of which \$95 million has been paid through September 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which include all program compounds) aggregating up to \$90 million in developmental milestones, \$290 million in first commercial sale milestones, and \$780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales. [1]

3. Collaborative Arrangements

Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck's more significant collaborative arrangements are discussed below.

AstraZeneca PLC

In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca's Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca ~~will develop~~ are developing and ~~commercialize~~ commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, *Keytruda* (pembrolizumab) and *Imfinzi*. The companies are also jointly developing and commercializing AstraZeneca's Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck ~~will~~ share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.

Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of *Research and development expenses*. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to *Research and development costs*.

- 7 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.

In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a \$600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a \$600 million liability (which remained accrued at September 30, 2023 March 31, 2024) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized \$250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first nine months of 2022. Additionally, in the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of \$400 million. Potential future sales-based milestone payments of \$2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca of \$105 million (which had been previously accrued for). In the second quarter of 2023, Lynparza received a regulatory approval triggering a future milestone payment of up to \$245 million from Merck to AstraZeneca. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of \$250 million from Merck to AstraZeneca (all of which were paid \$245 million and \$105 million in the first nine months quarter of 2022) 2024 and 2023, respectively (each of which had been previously accrued for). Potential future regulatory milestone payments of \$850 million \$650 million remain under the agreement.

The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was ~~\$1.6 billion~~ \$1.4 billion at September 30, 2023 March 31, 2024 and is included in *Other Intangibles, Net*. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.

- 8 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Summarized financial information related to this collaboration is as follows:

		Three Months Ended September 30,	Nine Months Ended September 30,	
		Three Months Ended March 31,		
		Three Months Ended March 31,		
(\$ in millions)				
	(\$ in millions)		2023	2022
			2023	2022

Alliance revenue -	Alliance revenue -								
Lynparza	Lynparza	\$	299	\$	284	\$	884	\$	825
Alliance revenue - Lynparza									
Alliance revenue - Lynparza									
Alliance revenue -	Alliance revenue -								
Koselugo	Koselugo		26		10		74		43
Alliance revenue - Koselugo									
Alliance revenue - Koselugo									
Total alliance revenue									
Total alliance revenue									
Total alliance revenue	Total alliance revenue	\$	325	\$	294	\$	958	\$	868
Cost of sales ⁽¹⁾	Cost of sales ⁽¹⁾		82		64		230		425
Cost of sales ⁽¹⁾									
Cost of sales ⁽¹⁾									
Selling, general and	Selling, general and								
administrative	administrative		44		45		143		135
Selling, general and administrative									
Selling, general and administrative									
Research and development									
Research and development									
Research and	Research and								
development	development		23		28		65		79
(\$ in millions)	(\$ in millions)						September 30, 2023		December 31, 2022
(\$ in millions)									
(\$ in millions)									
Receivables from AstraZeneca included in									
Other current assets									
Receivables from AstraZeneca included in									
Other current assets									
Receivables from	Receivables from								
AstraZeneca included	AstraZeneca included								
in Other current assets	in Other current assets								
		\$							
		337							
		\$							
		303							
Payables to	Payables to								
AstraZeneca	AstraZeneca								
included in Accrued	included in Accrued								
and other current	and other current								
liabilities ⁽²⁾	liabilities ⁽²⁾								
		257							
		123							
Payables to AstraZeneca included in Accrued									
and other current liabilities ⁽²⁾									
Payables to AstraZeneca included in Accrued									
and other current liabilities ⁽²⁾									
Payables to	Payables to								
AstraZeneca included	AstraZeneca included								
in Other Noncurrent	in Other Noncurrent								
Liabilities ⁽²⁾	Liabilities ⁽²⁾								
		600							
		600							
Payables to AstraZeneca included in Other									
Noncurrent Liabilities ⁽²⁾									
Payables to AstraZeneca included in Other									
Noncurrent Liabilities ⁽²⁾									

⁽¹⁾ Represents amortization of capitalized milestone payments. *Amount in the first nine months of 2022 includes \$250 million of cumulative amortization catch-up expense as noted above.*

⁽²⁾ Includes accrued milestone payments.

Eisai Co., Ltd.

In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai **will develop** are developing and **commercialize** **commercializing** Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in *Research and development* expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.

Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.

In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a \$125 million sales-based milestone payment from Merck to Eisai. Similarly, in the third quarter of 2023 an additional \$125 million sales-based milestone payment to Eisai was deemed by the Company to be probable of payment. Accordingly, Merck recorded \$250 million of liabilities for these payments (of which \$125 million was subsequently paid in the second quarter of 2023 and \$125 million remained accrued at March 31, 2024) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized \$81 million and \$154 million of cumulative amortization catch-up expense related to the recognition of these milestones in the first and third quarter and first nine months quarters of 2023, respectively. The sales-based milestone payment that was accrued in the first quarter of 2023 was paid to Eisai in the second quarter of 2023. In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating \$600 million. Potential future sales-based milestone payments of \$2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of \$50 million from Merck to Eisai (all of which were paid in the first nine months of 2022). There are no regulatory milestone payments remaining under the agreement.

The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was \$743 million \$623 million at September 30, 2023 March 31, 2024 and is included in *Other Intangibles, Net*. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

- 98 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Summarized financial information related to this collaboration is as follows:

		Three Months Ended		Nine Months Ended	
		September 30,		September 30,	
		Three Months Ended		Nine Months Ended	
		March 31,		September 30,	
		Three Months Ended		September 30,	
		March 31,		September 30,	
		Three Months Ended		September 30,	
		March 31,		September 30,	
(\$ in millions)	(\$ in millions)	2023	2022	2023	2022
(\$ in millions)	(\$ in millions)				
(\$ in millions)	(\$ in millions)				
Alliance revenue - Lenvima					
Alliance revenue - Lenvima					
Alliance revenue - Lenvima	Alliance revenue - Lenvima	\$ 260	\$ 202	\$ 734	\$ 660
Cost of sales (1)	Cost of sales (1)	137	53	320	159
Cost of sales (1)					
Cost of sales (1)					
Selling, general and administrative	Selling, general and administrative	46	42	145	115
Selling, general and administrative					
Research and development					
Research and development					
Research and development	Research and development	5	24	61	128
(\$ in millions)	(\$ in millions)			September 30, 2023	December 31, 2022
(\$ in millions)	(\$ in millions)				
(\$ in millions)	(\$ in millions)				

Receivables from Eisai included in <i>Other current assets</i>					
Receivables from Eisai included in <i>Other current assets</i>					
Receivables from Eisai included in <i>Other current assets</i>	Receivables from Eisai included in <i>Other current assets</i>		\$ 260	\$ 214	
Payables to Eisai included in <i>Accrued and other current liabilities</i> (2)	Payables to Eisai included in <i>Accrued and other current liabilities</i> (2)		125	—	
Payables to Eisai included in <i>Accrued and other current liabilities</i> (2)					
Payables to Eisai included in <i>Accrued and other current liabilities</i> (2)					

(i) Represents amortization of capitalized milestone payments. *Amounts* *Amount in the third first quarter and first ninemonths of 2023 include \$81 includes \$72 million and \$154 million, respectively,* of cumulative amortization catch-up expense as noted above.

(2) Represents an accrued milestone payment.

Bayer AG

In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer's Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. *The collaboration also includes development of Bayer's Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021 and has since been approved in several other markets.* Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer's share of profits from sales in Merck's marketing territories.

In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. *In the first nine months of 2022, Merck made the final \$400 million There are no sales-based milestone payment payments remaining under this collaboration to Bayer collaboration.*

The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were *\$533 million \$483 million and \$51 million \$49 million*, respectively, at *September 30, 2023* *March 31, 2024* and are included in *Other Intangibles, Net*. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.

Summarized financial information related to this collaboration is as follows:

		Three Months Ended		Nine Months Ended	
		September 30,		September 30,	
		Three Months Ended		Nine Months Ended	
		March 31,		September 30,	
		Three Months Ended		Nine Months Ended	
		March 31,		September 30,	
		Three Months Ended		Nine Months Ended	
		March 31,		September 30,	
(\$ in millions)					
(\$ in millions)					
(\$ in millions)	(\$ in millions)	2023	2022	2023	2022
Alliance revenue - Adempas/Verquvo	Alliance revenue - Adempas/Verquvo	\$ 92	\$ 88	\$ 259	\$ 258
Alliance revenue - Adempas/Verquvo					
Alliance revenue - Adempas/Verquvo					
Net sales of Adempas recorded by Merck					
Net sales of Adempas recorded by Merck					
Net sales of Adempas recorded by Merck	Net sales of Adempas recorded by Merck	65	57	189	181
Net sales of Verquvo recorded by Merck	Net sales of Verquvo recorded by Merck	8	6	24	15
Net sales of Verquvo recorded by Merck					
Net sales of Verquvo recorded by Merck					

Total sales										
Total sales										
Total sales	Total sales	\$	165	\$	151	\$	472	\$	454	
Cost of sales ⁽¹⁾	Cost of sales ⁽¹⁾		53		55		165		158	
Cost of sales ⁽¹⁾										
Cost of sales ⁽¹⁾										
Selling, general and administrative	Selling, general and administrative		33		42		100		107	
Selling, general and administrative										
Research and development										
Research and development										
Research and development	Research and development		26		18		76		52	
(\$ in millions)	(\$ in millions)						September 30, 2023		December 31, 2022	
(\$ in millions)	(\$ in millions)									
Receivables from Bayer included in <i>Other current assets</i>										
Receivables from Bayer included in <i>Other current assets</i>										
Receivables from Bayer included in <i>Other current assets</i>	Receivables from Bayer included in <i>Other current assets</i>						\$	157	\$	143
Payables to Bayer included in <i>Accrued and other current liabilities</i>	Payables to Bayer included in <i>Accrued and other current liabilities</i>							82		80
Payables to Bayer included in <i>Accrued and other current liabilities</i>										
Payables to Bayer included in <i>Accrued and other current liabilities</i>										

⁽¹⁾ Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer's share of profits from sales in Merck's marketing territories.

Ridgeback Biotherapeutics LP

In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop *Lagevrio* (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize *Lagevrio* and

- 10 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, *Lagevrio* has since received multiple additional authorizations worldwide, authorizations.

- 9 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within *Cost of sales*. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback's share of profits) are reflected as decreases to *Research and development* expenses.

Summarized financial information related to this collaboration is as follows:

(\$ in millions)	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
Net sales of Lagevrio recorded by Merck	\$ 640	\$ 436	\$ 1,236	\$ 4,859
Cost of sales (1)(2)	348	244	762	2,586
Selling, general and administrative (2)	21	48	72	117
Research and development (2)	8	18	33	74
(\$ in millions)				
Payables to Ridgeback included in Accrued and other current liabilities (3)	\$ 242	\$ 348		

(\$ in millions)	Three Months Ended	
	March 31,	2024
Net sales of Lagevrio recorded by Merck	\$ 350	\$ 392
Cost of sales (1)	191	221
Selling, general and administrative	16	27
Research and development	(5)	16
(\$ in millions)		
Payables to Ridgeback included in Accrued and other current liabilities (2)	\$ 160	\$ 113

(1) Includes cost of products sold by Merck, Ridgeback's share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.

(2) Expenses include an allocation for overhead charges.

(3) Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.

Bristol-Myers Squibb Company

Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to \$80 million. Alliance revenue related to this collaboration (recorded within Sales) consists of royalties and, for the first nine months of 2022, also includes the receipt of a regulatory approval milestone payment of \$20 million. Merck recorded alliance revenue related to this collaboration of \$52 million and \$142 million in the third quarter and first nine months of 2023, respectively, compared with \$39 million and \$124 million in the third quarter and first nine months of 2022, respectively.

Daiichi Sankyo

In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo's DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.

Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling \$4.0 billion in 2023. These payments included \$1.0 billion (\$500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provides for a continuation payment of \$750 million related to patritumab deruxtecan due from Merck in October 2024 and a continuation payment of \$750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck may opt out of does not make the collaboration continuation payments on the dates noted for either patritumab deruxtecan and/or raludotatug deruxtecan, by electing not to pay the rights for the applicable continuation payment. If Merck opts out of patritumab deruxtecan and/or raludotatug deruxtecan, program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo and rights related to such DXd ADCs will be returned to Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional \$5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones. In conjunction with this transaction, Merck recorded an aggregate pretax charge of \$5.5 billion to Research and development expenses in the fourth quarter of 2023 for the \$4.0 billion of upfront payments and the \$1.5 billion of continuation payments.

Merck and Daiichi Sankyo will equally share research and development costs, except for raludotatug deruxtecan, where Merck will be responsible for 75% of the first \$2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue. For raludotatug deruxtecan, Merck will be responsible for 75% of the first \$2.0 billion of research and development expenses; the companies will share equally all other

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

expenses Summarized financial information related to this collaboration is as well as follows:

(\$ in millions)	Three Months Ended	
	March 31,	2023
Selling, general and administrative	\$ 3	\$ —
Research and development	69	—
 (\$ in millions)	March 31, 2024	December 31, 2023
Payables to Daiichi Sankyo included in <i>Accrued and other current liabilities</i>	\$ 817	\$ 800
Payables to Daiichi Sankyo included in <i>Other Noncurrent Liabilities</i>	750	750

Moderna, Inc.

In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials. Merck and Moderna will share costs and any profits worldwide, equally under this worldwide collaboration. Merck will include records its share of development costs associated with the collaboration as part of *Research and development* expenses.

In conjunction with this transaction, Merck will record an aggregate pretax charge of \$5.5 billion. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to *Research and development* expenses costs. Merck has also capitalized certain of the shared costs, which aggregated \$110 million at March 31, 2024 and will be amortized over the assets' estimated useful lives.

Summarized financial information related to this collaboration is as follows:

(\$ in millions)	Three Months Ended	
	March 31,	2023
Selling, general and administrative	\$ 2	\$ 1
Research and development	69	26
 (\$ in millions)	March 31, 2024	December 31, 2023
Payables to Moderna included in <i>Accrued and other current liabilities</i>	\$ 72	\$ 63

Bristol-Myers Squibb Company

Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the fourth U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to \$80 million. Alliance revenue related to this collaboration, consisting of royalties (recorded within *Sales*) was \$71 million and \$43 million in the first quarter of 2024 and 2023, for the \$4.0 billion upfront payments and the \$1.5 billion in continuation payments, respectively.

4. Spin-Off Restructuring

In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of Organon & Co.

On June 2, 2021, Merck the Company's Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the spin-off of Organon through a distribution of Organon's publicly traded stock to Company shareholders. In connection 2031, with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements cumulative pretax costs to effect be incurred by the spin-off and provide a framework for Company to implement the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. A majority program estimated to be approximately \$4.0 billion. Approximately 60% of the services provided under cumulative pretax costs will be non-cash, relating primarily to the TSA terminated within 25 months following the spin-off; a majority accelerated depreciation of facilities to be closed or divested. The remainder of the remaining services costs will terminate within 35 months following result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of \$246 million in the spin-off. Merck and Organon also entered into a series first quarter of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior 2024 related to the separation, Merck is continuing 2024 Restructuring Program, bringing total cumulative pretax costs incurred through March 31, 2024 to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in

accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.

The amounts included in the condensed consolidated statement of income for the above MSAs include sales of \$100 million and \$100 million and related cost of sales of \$106 million and \$104 million for the third quarter of 2023 and 2022, respectively, and sales of \$290 million and \$293 million and related cost of sales of \$314 million and \$312 million for the first nine months of 2023 and 2022, respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September 30, 2023 and September 30, 2022. \$436 million.

The amounts due from Organon under all of the above agreements were \$526 million and \$511 million at September 30, 2023 and December 31, 2022, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were \$385 million and \$345 million at September 30, 2023 and December 31, 2022, respectively, and are included in Accrued and other current liabilities.

5. Restructuring

In 2019, Merck approved a global restructuring program (Restructuring (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company's manufacturing and supply network, as well as reducing its global real estate footprint. The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately \$4.0 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.

The Company recorded total pretax costs of \$199 million and \$175 million \$97 million in the third first quarter of 2023 and 2022, respectively, and \$532 million and \$559 million for related to the first nine months 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, 2022, respectively, related to restructuring program activities. Since inception as of January 1, 2024, any remaining activities are now being accounted for as part of the Restructuring Program through September 30, 2023, Merck has recorded total pretax accumulated costs of approximately \$3.9 billion. For the full year of 2023, the Company expects to record charges of approximately \$650 million related to the 2024 Restructuring Program.

For segment reporting, restructuring charges are unallocated expenses.

- 1211 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The following tables summarize the charges related to the restructuring program activities programs by type of cost.

Restructuring costs	\$
	\$
	\$

(\$ in millions)	Three Months Ended September 30, 2022					Nine Months Ended September 30, 2022					
	Separation		Accelerated			Total	Separation		Accelerated		
	Costs	Depreciation	Other	Depreciation	Other		Costs	Depreciation	Other	Total	
Cost of sales	\$ —	\$ 16	\$ 38	\$ 54	\$ —	\$ 167	\$ —	\$ 51	\$ 116	\$ 167	
Selling, general and administrative	—	5	21	26	—	74	—	17	57	74	
Research and development	—	—	1	1	—	30	—	29	1	30	
Restructuring costs	65	—	29	94	197	288	—	—	91	288	
	\$ 65	\$ 21	\$ 89	\$ 175	\$ 197	\$ 559	\$ 97	\$ 265	\$ 265	\$ 559	

Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.

(\$ in millions)	Three Months Ended March 31, 2023			
	Accelerated Depreciation	Separation Costs	Other Exit Costs	Total
2019 Restructuring Program				
Cost of sales	\$ 21	\$ —	\$ 8	\$ 29
Selling, general and administrative	—	—	1	1
Restructuring costs	—	41	26	67
	\$ 21	\$ 41	\$ 35	\$ 97

Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the [program](#) programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites [have](#) and [will](#) continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.

Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.

Other [activity exit costs](#) in 2024 and 2023 and 2022 [includes](#) include asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note [12](#) 9) and share-based compensation.

The following table summarizes the charges and spending relating to restructuring program activities for the [nine](#) [three](#) months ended [September 30, 2023](#) [March 31, 2024](#):

(\$ in millions)	(\$ in millions)	Separation			Accelerated Depreciation		Separation Costs	Other Exit Costs	Total
		Costs	Depreciation	Other	Total	(\$ in millions)			
Restructuring reserves									
January 1, 2023	\$ 479	\$ —	\$ 34	\$ 513					
Restructuring reserves									
January 1, 2024									
Expenses	Expenses	246	79	207	532				
(Payments)	(Payments)								
receipts, net	receipts, net								
		(191)	—	(103)	(294)				
Non-cash activity	Non-cash activity	—	(79)	(105)	(184)				
Restructuring reserves									
September 30, 2023 ⁽¹⁾	\$ 534	\$ —	\$ 33	\$ 567					
Restructuring reserves									
March 31, 2024									

⁽¹⁾ The remaining cash outlays are expected to be largely completed by the end of 2025.

6.5. Financial Instruments

Derivative Instruments and Hedging Activities

The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.

A significant portion of the Company's revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company's foreign currency risk management program, as well as its interest rate risk management activities are discussed below.

Foreign Currency Risk Management

The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.

- 13 12 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and **foreign** exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.

The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or *Other comprehensive income (OCI)*, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in *Accumulated Other Comprehensive Loss (AOCL)* and reclassified into *Sales* when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in *Sales* each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.

The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of **foreign** exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in *Other (income) expense, net*. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of **exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument.** The forward contracts are not designated as hedges and are marked to market through *Other (income) expense, net*. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.

The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in **foreign** exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within *OCI* and remain in *AOCL* until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in *OCI*. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.

Foreign exchange risk is also managed through the use of foreign currency debt. The Company's senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within *OCI*.

The effects of the Company's net investment hedges on *OCI* and the Condensed Consolidated Statement of **Operations Income** are shown below:

		Amount of Pretax (Gain)			
		Loss Recognized in			
		<i>Other (income)</i>			
Amount of Pretax (Gain) Loss		Recognized in Other	expense, net for	Amounts Excluded from	
		Comprehensive Income (i)		Effectiveness Testing	
				Three	Nine
				Months	Months
Three Months	Ended	Ended	Ended	Three Months	Nine Months
Ended	September	September	September	Ended	Ended
September 30,	30,	30,	30,		

Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (2)							
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (2)							
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (2)							
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (2)							
Three Months Ended March 31, (\$ in millions)		Amount of Pretax Loss Recognized in <i>Other (income) expense, net</i> for Amounts Excluded from Effectiveness Testing					
(\$ in millions)							
(\$ in millions)	(\$ in millions)	2023 2022 2023 2022 2023 2022 2023 2022					
<i>Net Investment</i>	<i>Net Investment</i>						
<i>Hedging</i>	<i>Hedging</i>						
<i>Relationships</i>	<i>Relationships</i>						
<i>Net Investment Hedging</i>							
<i>Relationships</i>							
<i>Net Investment Hedging</i>							
<i>Relationships</i>							
Foreign exchange contracts	Foreign exchange contracts	\$ (1)	\$ (1)	\$—	\$ (47)	\$—	\$—
Foreign exchange contracts	Foreign exchange contracts	\$—	\$—	\$—	\$—	\$ 1	\$ (2)
Euro-denominated notes	Euro-denominated notes	(100)	(250)	(26)	(431)	—	—
Euro-denominated notes	Euro-denominated notes	—	—	—	—	—	—
Euro-denominated notes	Euro-denominated notes	—	—	—	—	—	—

(2) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.

- 14 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Interest Rate Risk Management

The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.

- 13 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

At **September 30, 2023** **March 31, 2024**, the Company was a party to **three** **four** pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.

September 30, 2023						March 31, 2024					
										March 31, 2024	
										March 31, 2024	
(\$ in millions)	(\$ in millions)	Value of Debt	Number of Interest Swaps Held	Par Rate	Total Swap Notional Amount (\$ in millions)	Par Value of Debt	Number of Interest Rate Swaps Held				Total Swap Notional Amount
4.50% notes due 2033	4.50% notes due 2033	\$1,500	3	\$ 750							

The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value **change** **changes** in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. In **October 2023**, the Company entered into an additional interest rate swap with a notional amount of \$250 million also related to its 4.50% notes due 2033. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. In **April 2024**, the Company entered into two additional interest rate swaps with notional amounts of \$250 million each also related to its 4.50% notes due 2033.

The table below presents the location of amounts recorded **on** **in** the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:

		Cumulative Amount of Fair Value Hedging Adjustment Increase					
		Carrying Amount of Hedged Liabilities	(Decrease) Included in the Carrying Amount				
		Carrying Amount of Hedged Liabilities		Carrying Amount of Hedged Liabilities	Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount		
(\$ in millions)	(\$ in millions)	September 30, 2023	December 31, 2022	September 30, 2023	December 31, 2022	(\$ in millions)	March 31, 2024
Balance Sheet Line Item in which Hedged Item is Included							December 31, 2023
Balance Sheet Caption							December 31, 2023
Long-Term Debt	Long-Term Debt	\$ 743	\$ —	\$ (7)	\$ —		
Long-Term Debt	Long-Term Debt						
Long-Term Debt	Long-Term Debt						

Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:

		September 30, 2023			December 31, 2022			March 31, 2024			December 31, 2023		
		Fair Value of Derivative		U.S. Dollar	Fair Value of Derivative		U.S. Dollar	Fair Value of Derivative		U.S. Dollar	Fair Value of Derivative		U.S. Dollar
		Asset	Liability	Notional									
Derivatives	Derivatives												
Designated as Hedging Instruments	Designated as Hedging Instruments												
Instruments	Instruments												
Derivatives Designated as Hedging Instruments	Derivatives Designated as Hedging Instruments												
Derivatives Designated as Hedging Instruments	Derivatives Designated as Hedging Instruments												
Interest rate swap contracts	Interest rate swap contracts												
Interest rate swap contracts	Interest rate swap contracts												

Interest rate swap contracts	Interest rate swap contracts	Other Noncurrent Liabilities	\$ —	\$ 8	\$ 750	\$ —	\$ —	\$ —
Foreign exchange contracts	Foreign exchange contracts	Other current assets	321	—	8,059	220	—	4,824
Foreign exchange contracts	Foreign exchange contracts	Assets	51	—	1,746	27	—	1,609
Foreign exchange contracts	Foreign exchange contracts	Accrued and other liabilities	—	4	680	—	101	2,691
Foreign exchange contracts	Foreign exchange contracts	Other Noncurrent Liabilities	—	1	178	—	1	91
			\$ 372	\$ 13	\$ 11,413	\$ 247	\$ 102	\$ 9,215
Derivatives Not Designated as Instruments	Derivatives Not Designated as Instruments	Derivatives Not Designated as Hedging Instruments						
Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts	Foreign exchange contracts
Foreign exchange contracts	Foreign exchange contracts	Accrued and other liabilities	—	163	9,910	—	307	10,926
			\$ 229	\$ 163	\$ 18,395	\$ 186	\$ 307	\$ 19,466
			\$ 601	\$ 176	\$ 29,808	\$ 433	\$ 409	\$ 28,681

As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see *Concentrations of Credit Risk* below). The following table provides information on the Company's derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:

(\$ in millions)	September 30, 2023				December 31, 2022				March 31, 2024				December 31, 2023					
	Asset		Liability															
	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	Gross amounts recognized in the condensed consolidated balance sheet	
Gross amounts recognized in the condensed consolidated balance sheet	\$ 601	\$ 176	\$ 29,808	\$ 433	\$ 409	\$ 28,681												

Gross amounts	Gross amounts
subject to	subject to
offset in	offset in
master	master
netting	netting
arrangements	arrangements
not offset in	not offset in
the	the
condensed	condensed
consolidated	consolidated
balance sheet	balance sheet (138) (138) (220) (220)
Cash collateral received/posted	(143) — (66) (19)
Cash collateral received	
Net amounts	Net amounts \$320 \$ 38 \$147 \$170

15 14 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:

		Three Months Ended September 30,				Nine Months Ended September 30,											
		Three Months Ended March 31,				Three Months Ended March 31,											
		Three Months Ended March 31,				Three Months Ended March 31,											
(\$ in millions)																	
(\$ in millions)																	
(\$ in millions)	(\$ in millions)	2023	2022	2023	2022	2023	2022	2023	2022								
Financial Statement	Financial Statement																
Caption in which	Caption in which																
Effects of Fair Value or	Effects of Fair Value or																
Cash Flow Hedges are	Cash Flow Hedges are																
Recorded	Recorded																
		Sales															
				(1)		(loss)											
		\$ 15,962	\$ 14,959	\$ 126	\$ 429	\$ (16)	\$ (416)	\$ 45,485	\$ 45,453								
Financial Statement Caption in which Effects of																	
Fair Value or Cash Flow																	
Hedges are Recorded																	
Financial Statement Caption in which Effects of																	
Fair Value or Cash Flow																	
Hedges are Recorded																	
		\$															
		\$															
		\$															
(Gain) loss on fair value hedging relationships:																	
(Gain) loss on fair value hedging relationships:																	
(Gain) loss on fair value (Gain) loss on fair value																	
hedging relationships: hedging relationships:																	
Interest rate swap	Interest rate swap																
contracts	contracts																
Interest rate swap contracts																	
Interest rate swap contracts																	
Hedged items																	
Hedged items																	
Hedged items	Hedged items	—	—	(7)	1	—	—	(7)	(13)								

Derivatives designated as hedging instruments	Derivatives designated as hedging instruments	—	—	8	—	—	—	—	—	8	4	—	—
Derivatives designated as hedging instruments													
Derivatives designated as hedging instruments													
Impact of cash flow hedging relationships:													
Impact of cash flow hedging relationships:													
Impact of cash flow hedging relationships:	Impact of cash flow hedging relationships:												
Foreign exchange contracts	Foreign exchange contracts												
Amount of gain recognized in OCI on derivatives													
Foreign exchange contracts													
Foreign exchange contracts													
Amount of gain (loss) recognized in OCI on derivatives													
Amount of gain (loss) recognized in OCI on derivatives													
Amount of gain (loss) recognized in OCI on derivatives													
Increase in Sales as a result of AOCL reclassifications													
Increase in Sales as a result of AOCL reclassifications													
Increase in Sales as a result of AOCL reclassifications	Increase in Sales as a result of AOCL reclassifications	45	253	—	—	(45)	(253)	170	491	—	—	(170)	(491)
Interest rate contracts	Interest rate contracts												
Interest rate contracts													
Interest rate contracts													
Amount of gain recognized in derivatives	Amount of gain recognized in derivatives												
Other (income) expense, net on derivatives	Other (income) expense, net on derivatives	—	—	—	(1)	—	—	—	—	(1)	(2)	—	—
Amount of (loss) gain recognized in OCI on derivatives													
Amount of gain recognized in Other (income) expense, net on derivatives													
Amount of gain recognized in Other (income) expense, net on derivatives													
Amount of loss recognized in OCI on derivatives													
Amount of loss recognized in OCI on derivatives													
Amount of loss recognized in OCI on derivatives													

^(a) Interest expense is a component of Other (income) expense, net.

The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:

		Amount of Derivative Pretax (Gain) Loss Recognized in Income							
		Three Months Ended September 30,		Nine Months Ended September 30,					
		Amount of Derivative Pretax (Gain) Loss Recognized in Income		Amount of Derivative Pretax (Gain) Loss Recognized in Income					
		Amount of Derivative Pretax (Gain) Loss Recognized in Income		Amount of Derivative Pretax (Gain) Loss Recognized in Income					
Three Months Ended March 31,									
(\$ in millions)									
(\$ in millions)									
(\$ in millions)	(\$ in millions)	2023		2022					
Derivatives Not Designated as Hedging Instruments	Derivatives Not Designated as Hedging Instruments	Income Statement		Caption					
<i>Derivatives Not Designated as Hedging Instruments</i>									
<i>Derivatives Not Designated as Hedging Instruments</i>									
Foreign exchange contracts ⁽¹⁾									
Foreign exchange contracts ⁽¹⁾									
Foreign exchange contracts ⁽¹⁾									
Foreign exchange contracts ^{(1) (2)}	Foreign exchange contracts ^{(1) (2)}	Other (income) expense, net	\$ 60	\$ (41)	\$ 32				
Foreign exchange contracts ⁽²⁾		Sales	—	(4)	(3)				
<i>Foreign exchange contracts ^{(1) (2)}</i>									
<i>Foreign exchange contracts ^{(1) (2)}</i>									

(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.

(2) These derivative contracts serve as economic hedges of forecasted transactions.

At September 30, 2023 March 31, 2024, the Company estimates \$269 million \$113 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOC to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.

- 16 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Investments in Debt and Equity Securities

Information on investments in debt and equity securities is as follows:

(\$ in millions)	(\$ in millions)	September 30, 2023			December 31, 2022			March 31, 2024			December 31, 2023		
		Amortized Cost	Gross Gains	Unrealized Losses	Fair Value	Amortized Cost	Gross Gains	Unrealized Losses	Fair Value	Amortized Cost	Gross Gains	Unrealized Losses	Fair Value
Commercial paper	Commercial paper	\$ 168	\$ —	\$ —	\$ 168	\$ 498	\$ —	\$ —	\$ 498				
Commercial paper													
Commercial paper													
U.S. government securities	U.S. government securities	67	—	—	67	68	—	—	68				
Corporate notes and bonds	Corporate notes and bonds	12	—	—	12	3	—	—	3				

Total debt securities	Total debt securities	\$ 247 \$ — \$ — \$ 247 \$ 569 \$ — \$ — \$ 569
Publicly traded equity securities (1)	Publicly traded equity securities (1)	1,746 1,284
Total debt and publicly traded equity securities	Total debt and publicly traded equity securities	\$1,993 \$1,853

(1) Unrealized net gains of \$61 million and \$327 \$143 million were recorded in Other (income) expense, net in the third first quarter and first nine months of 2023, respectively, 2024 on equity securities still held at September 30, 2023 March 31, 2024. Unrealized net losses gains of \$221 million and \$415 million \$338 million were recorded in Other (income) expense, net in the third first quarter and first nine months of 2022, respectively, 2023 on equity securities still held at September 30, 2022 March 31, 2023.

At September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023, the Company also had \$863 million \$851 million and \$705 million \$942 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first nine months quarter of 2024, the Company recorded unrealized gains of \$4 million and unrealized losses of \$5 million related to certain of these equity investments still held at March 31, 2024. During the first quarter of 2023, the Company recorded unrealized gains of \$7 million \$1 million and unrealized losses of \$24 \$21 million related to certain of these equity investments still held at September 30, 2023. During the first nine months of 2022, the Company recorded unrealized gains of \$21 million and unrealized losses of \$12 million related to certain of these equity investments still held at September 30, 2022 March 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable

- 15 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

price changes for investments in equity investments without readily determinable fair values still held at September 30, 2023 March 31, 2024 were \$296 million \$297 million and \$40 million \$69 million, respectively.

At September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023, the Company also had \$467 \$396 million and \$655 \$725 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were \$93 \$2 million and \$141 million for the third quarter of 2023 and 2022, respectively, and were \$66 million and \$952 \$132 million for the first nine months quarter of 2023 2024 and 2022, 2023, respectively.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or **liabilities**;

Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or **liabilities**;

Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

- 17 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below:

Fair Value Measurements Using	Fair Value Measurements Using
Fair Value Measurements Using	Fair Value Measurements Using

		Level 1			Level 2			Level 1			Level 2			Level 3			
		Level 1	2	3	Total	Level 1	2	3	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
(\$ in millions)		(\$ in millions)		September 30, 2023			December 31, 2022			(\$ in millions)		March 31, 2024			December 31, 2023		
Assets	Assets																
<i>Investments</i>	<i>Investments</i>																
<i>Investments</i>																	
Commercial paper	Commercial paper	\$ —	\$ 168	\$ —	\$ 168	\$ —	\$ 498	\$ —	\$ 498								
Commercial paper																	
Commercial paper																	
Publicly traded equity securities	Publicly traded equity securities	1,306	—	—	1,306	1,015	—	—	1,015								
		1,306	168	—	1,474	1,015	498	—	1,513								
<i>Other assets (1)</i>	<i>Other assets (1)</i>																
U.S. government and agency securities	U.S. government and agency securities	67	—	—	67	68	—	—	68								
U.S. government and agency securities																	
U.S. government and agency securities																	
Corporate notes and bonds	Corporate notes and bonds	12	—	—	12	3	—	—	3								
Publicly traded equity securities (2)	Publicly traded equity securities (2)	440	—	—	440	269	—	—	269								
		519	—	—	519	340	—	—	340								
		705															
<i>Derivative assets (3)</i>	<i>Derivative assets (3)</i>																
Forward exchange contracts	Forward exchange contracts	—	431	—	431	—	218	—	218								
Forward exchange contracts																	
Purchased currency options	Purchased currency options	—	170	—	170	—	215	—	215								
Interest rate swaps																	
		—	601	—	601	—	433	—	433								
Total assets	Total assets	\$1,825	\$769	\$ —	\$2,594	\$1,355	\$931	\$ —	\$2,286								
Liabilities	Liabilities																
<i>Other liabilities</i>	<i>Other liabilities</i>																
<i>Other liabilities</i>																	
Other liabilities																	
Contingent consideration	Contingent consideration																
Contingent consideration																	
Contingent consideration	Contingent consideration	\$ —	\$ —	\$ 345	\$ 345	\$ —	\$ —	\$ 456	\$ 456								

Derivative liabilities ⁽³⁾	Derivative liabilities ⁽³⁾
Forward exchange contracts	Forward exchange contracts
Written currency options	Written currency options
Interest rate swaps	Interest rate swaps
	— 176 — 176 — 409 — 409
	—
Total liabilities	Total liabilities \$ — \$176 \$345 \$ 521 \$ — \$409 \$456 \$ 865

(2) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.

(2) Balance at **September 30, 2023** **March 31, 2024** includes securities with a **total** fair value of **\$132** **\$266** million, which are subject to a contractual sale restriction that expires in July 2024.

(3) The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company's own credit risk, the effects of which were not significant.

As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, Cash and cash equivalents included **\$7.8 billion** **\$4.6 billion** and **\$11.3 billion** **\$6.0 billion** of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).

- 16 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Contingent Consideration

Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:

(\$ in millions)	(\$ in millions)	2023	2022	(\$ in millions)	2024	2023
Fair value	Fair value					
January 1	January 1	\$ 456	\$ 777			
Changes in estimated fair value	Changes in estimated fair value					
(1)	(2)	6	(156)			
Payments	Payments	(117)	(119)			
Other	—	(3)				
Fair value						
September 30 ⁽²⁾	\$ 345	\$ 499				
Fair value						
March 31						
(2)						

(2) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.

(2) At **September 30, 2023** Balance at **March 31, 2024**, **\$255 million** includes **\$133 million** of the **current** liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. **Balance at September 30, 2023** includes **\$126 million** recorded as a **current** liability for amounts expected to be paid within the next 12 months.

The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.

- 18 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Other Fair Value Measurements

Some of the Company's financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

The estimated fair value of loans payable and long-term debt (including current portion) at **September 30, 2023** **March 31, 2024**, was **\$29.5 billion** **\$30.4 billion** compared with a carrying value of **\$34.9 billion** **\$34.2 billion** and at **December 31, 2022** **December 31, 2023**, was **\$26.7 billion** **\$32.0 billion** compared with a carrying value of **\$30.7 billion** **\$35.1 billion**. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.

Concentrations of Credit Risk

On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company's investment policy guidelines.

The majority of the Company's accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.

The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored **\$3.5 billion** **\$2.7 billion** and **\$2.5 billion** **\$3.0 billion** of accounts receivable as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the Company had collected **\$39** **\$43 million** and **\$67** **\$44 million**, respectively, on behalf of the financial institutions, which is reflected as restricted cash in *Other current assets* and the related obligation to remit the cash within *Accrued and other current liabilities*. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was *de minimis*.

Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company's financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company's credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was **\$143 million** **\$58 million** and **\$66** **\$3 million** at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively. The obligation to return such collateral is recorded in *Accrued and other current liabilities*. **Cash collateral advanced by the Company to various counterparties was \$19 million at December 31, 2022.**

7.

- 17 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

6. Inventories

Inventories consisted of:

(\$ in millions)		September 30, 2023		December 31, 2022		(\$ in millions)	March 31, 2024	December 31, 2023
		(\$ in millions)	30, 2023	(\$ in millions)	31, 2022			
Finished goods	Finished goods	\$ 1,840		\$ 1,841				
Raw materials and work in process	Raw materials and work in process	7,630		7,063				
Supplies	Supplies	281		238				
Total	Total	9,751		9,142				
Decrease to LIFO cost	Decrease to LIFO cost	(469)		(293)				
		\$ 9,282		\$ 8,849				
Recognized as:	Recognized as:							
Inventories	Inventories	\$ 6,131		\$ 5,911				
Inventories								
Other Assets	Other Assets	3,151		2,938				

Amounts recognized as *Other Assets* are comprised almost entirely of raw materials and work in process inventories. At both **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, these amounts included **\$2.4 billion** **\$2.6 billion** of inventories not expected to be sold within one year. In addition, these amounts included **\$756 million** **\$861 million** and **\$516 million** **\$790 million** at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively, of inventories produced in preparation for product launches.

- 19 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

8. Other Intangibles

In the third quarter of 2022, the Company recorded \$887 million of impairment charges within *Research and development* expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQuie, Inc. Of this amount, \$807 million represents an in-process research and development (IPR&D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter of 2022, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the fair value of nemtabrutinib utilizing an income approach which uses Level 3 inputs to calculate the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&D impairment charge noted above. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which was expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a \$780 million impairment charge, which was recorded in the fourth quarter of 2022. The remaining IPR&D intangible asset related to nemtabrutinib is \$418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The remaining \$80 million intangible asset impairment charge in the third quarter of 2022 related to derazantinib and resulted from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.

9. Long-Term Debt

In May 2023, the Company issued \$6.0 billion principal amount of senior unsecured notes consisting of \$500 million of 4.05% notes due 2028, \$750 million of 4.30% notes due 2030, \$1.5 billion of 4.50% notes due 2033, \$750 million of 4.90% notes due 2044, \$1.5 billion of 5.00% notes due 2053, and \$1.0 billion of 5.15% notes due 2063.

The Company used a portion of the \$5.9 billion net proceeds from this offering to fund a portion of the cash consideration paid for the acquisition of Prometheus, including related fees and expenses, and used the remaining net proceeds for general corporate purposes including to repay commercial paper borrowings and other indebtedness with upcoming maturities.

10.7. Contingencies

The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company's financial condition, results of operations or cash flows.

Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.

The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

The Company's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.

Product Liability Litigation

Dr. Scholl's Foot Powder

Merck is a defendant in product liability lawsuits in the U.S. arising from consumers' alleged exposure to talc in Dr. Scholl's foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck's consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of March 31, 2024, approximately 275 cases were pending against Merck in various state courts.

Gardasil/Gardasil 9

As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving *Gardasil* (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and *Gardasil 9* (Human Papillomavirus 9-valent

- 20 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Vaccine, Recombinant). As of **September 30, 2023** **March 31, 2024**, approximately **95 190** cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with *Gardasil* or *Gardasil* 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the **U.S.** Judicial Panel on Multidistrict Litigation ordered that *Gardasil*/*Gardasil* 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. There are fewer than 15 product liability cases pending outside the U.S.

- 18 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Governmental Proceedings

Inflation Reduction Act

As previously disclosed, on June 6, 2023, Merck filed a complaint in the U.S. District Court for the District of Columbia against the U.S. government regarding the Inflation Reduction Act's "Drug Price Negotiation Program" for Medicare (the Program). This litigation seeks relief from the Program by challenging its constitutionality as violative of the First and Fifth Amendments to the U.S. Constitution.

Other Governmental Proceedings

As previously disclosed, from time to time, the Company's subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company's policy is to cooperate with these authorities and to provide responses as appropriate.

As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.

Commercial and Other Litigation

Zetia Antitrust Litigation

As previously disclosed, Merck, Merck Sharp & Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.

As previously disclosed, in April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck agreed to pay \$572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs' claims, which was recorded as an expense in the Company's financial results **for** **in the first nine months** **quarter of 2023**. On October 18, 2023, In October 2023, the court granted final approval of the indirect purchaser class settlement.

In 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending. MDL.

In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs' complaints, including any claims for Vytorin damages. That In December 2023, prior to a decision on the motion to dismiss, the Vytorin-related claims is still pending. U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). On March 15, 2024, the Merck Defendants filed motions to dismiss the Humana and Centene cases.

Qui Tam Litigation

As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company's M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators' motion for summary judgment, granted two of the Company's motions for summary judgment, and denied the Company's remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators' amended complaint in full with prejudice. Relators have appealed that decision. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M-M-R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck's motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is complete, and the parties filed and briefed cross-motions for summary judgment. On July 27, 2023, in the False Claims Act case, the court denied relators' motion for summary judgment, granted two of the Company's motions for summary judgment, and denied the Company's remaining motions for summary judgment as moot. The court entered judgment in favor of the Company.

- 21 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

and dismissed relators' amended complaint in full with prejudice. Relators have appealed that decision. In the antitrust case, the court granted the Company's motion for summary judgment as to plaintiffs' state law claims and denied the motion as to plaintiffs' antitrust claim. On October 20, 2023, the Company petitioned the Third Circuit for permission to appeal has appealed the antitrust decision.

Patent Litigation

From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company's products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company's patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.

- 19 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of **Bridion** (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 in December 2022 on this remaining PTE calculation defense defense.

As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck's favor. The court held that Merck's calculation of PTE for the sugammadex patent covering the compound is not invalid and held closing arguments on February 3, 2023, that the U.S. Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck's U.S. patent protection for **Bridion** through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.

In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending.

While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of **Bridion** to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of **Bridion** to the market before January 2026 or later, depending on any applicable pediatric exclusivity.

On June 13, 2023 February 5, 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of **Bridion** Injection. On March 15, 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey ruled in Merck's favor. The court held that Merck's calculation against Hikma, postponing FDA approval of PTE the Hikma generic drug for 30 months or until expiration of the sugammadex patent covering the compound is not invalid (January 27, 2026) and that the U.S. Patent & Trademark Office correctly granted a full 5-year extension. This ruling affirms and validates Merck's U.S. patent protection for **Bridion** through at least January 2026. On June 29, 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the pending or tentatively approved generic applications until January 27, 2026, except for patent, and any subsequent agreements between defendants and Merck or further order by potentially applicable pediatric exclusivity, will occur earlier than expiry of the court 30-month stay.

On July 24, 2023, defendants filed a notice of appeal with the Federal Court of Appeals.

Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to **Januvia** (sitagliptin), **Janumet** (sitagliptin/metformin HCl), and **Janumet XR** (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA's Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, **Januvia**, **Janumet**, and **Janumet XR** contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In

As previously disclosed, beginning in 2019, Par Pharmaceutical a number of generic drug companies filed suit against the Company in the U.S. District Court for the District ANDAs seeking approval of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions forms of **Januvia**, **Janumet**, and **Janumet XR** following expiration of key patent protection, but prior to along with paragraph IV certifications challenging the expiration validity of the 2027 salt/polymorph patent. The Company also filed a patent responded by filing infringement lawsuit against Mylan in the U.S. District Court for the Northern District of West Virginia.

Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with suits which have all defendants scheduled to participate in that trial. In the Company's case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the U.S. District Court for the Northern District of West Virginia issued a decision in the Company's favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit been settled. The parties have now settled the matter, and Viatris has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.

In total, the Company has settled with a total of 26 generic companies providing that these generic companies can bring their generic versions of **Januvia** and **Janumet** to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of **Janumet XR** to the market in July 2026 or earlier under certain circumstances.

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus's NDA seeking approval of its a form of sitagliptin tablets, that is a different form than that used in Januvia. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia product.

In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed a NDA an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA's Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.

- 20 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

As a result of these favorable court rulings and settlement agreements related to the later expiring 2027 salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company's sitagliptin products.

Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held on March 8, 2023, in March 2023 and an Advocate General Opinion is expected in the fourth quarter of 2023 June 2024 with a decision later in the first quarter of 2024. If the CJEU renders a decision that negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.

In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants' sitagliptin dihydrogen phosphate product, while the Company's patents and patent term extensions are in force. The lawsuit is in response to the Defendants' application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved on August 15, 2023. Merck asserts that the Defendants' activity infringes a patent term extension associated with Merck's patent directed to the sitagliptin compound patent.

Keytruda — The As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint on April 13, 2023, in April and May 2023, denying Merck's claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023, and March 13, 2024, the Company filed inter partes review petitions with the United States Patent & Trademark Office Patent Trial and Appeal Board, challenging the validity of all nine patents asserted in the case.

Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.

In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier.

Other Litigation

There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company's financial condition, results of operations or cash flows either individually or in the aggregate.

Legal Defense Reserves

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023** of approximately \$220 million and **\$230 million** **\$210 million**, respectively, represents the Company's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

- 23 21 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

11.8. Equity

Three Months Ended September 30,													Three Months Ended March 31,					
(\$ and shares in millions except per share amounts)	(\$ and shares in millions except per share amounts)	Common Stock			Accumulated Other			Treasury Stock			(\$ and shares in millions except per share amounts)	Common Stock			Treasury Stock			
		Shares	Par Value	Other	Paid-In Capital	Retained Earnings	Other	Shares	Cost	Non-controlling Interests		Paid-In Capital	Other	Retained Earnings	Other	Shares	Cost	Non-controlling Interests
Balance at July 1, 2022		3,577	\$ 1,788	\$ 44,115	\$ 58,437	\$ (4,327)	1,044	\$ (56,770)	\$ 75	\$ 43,318								
Net income attributable to Merck & Co., Inc.		—	—	—	3,248	—	—	—	—	—	3,248							
Other comprehensive loss, net of taxes		—	—	—	—	(416)	—	—	—	—	(416)							
Cash dividends declared on common stock (\$0.69 per share)		—	—	—	(1,757)	—	—	—	—	—	(1,757)							
Share-based compensation plans and other		—	—	128	—	—	—	12	—	—	140							
Net income attributable to noncontrolling interests		—	—	—	—	—	—	—	—	5	5							
Distributions attributable to noncontrolling interests		—	—	—	—	—	—	—	—	(14)	(14)							
Balance at September 30, 2022		3,577	\$ 1,788	\$ 44,243	\$ 59,928	\$ (4,743)	1,044	\$ (56,758)	\$ 66	\$ 44,524								
Balance at July 1, 2023		3,577	\$ 1,788	\$ 44,219	\$ 54,198	\$ (4,900)	1,038	\$ (56,612)	\$ 49	\$ 38,742								
Balance at January 1, 2023																		
Net income attributable to Merck & Co., Inc.	Net income attributable to Merck & Co., Inc.	—	—	—	4,745	—	—	—	—	—	4,745							
Other comprehensive loss, net of taxes	Other comprehensive loss, net of taxes	—	—	—	—	(16)	—	—	—	—	(16)							
Cash dividends declared on common stock (\$0.73 per share)	Cash dividends declared on common stock (\$0.73 per share)	—	—	—	(1,861)	—	—	—	—	—	(1,861)							
Treasury stock shares purchased	Treasury stock shares purchased	—	—	—	—	—	4	(466)	—	(466)								

Share-based compensation plans and other	Share-based compensation	139	—	—	12	—	151
Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	—	—	—	—	—	5 5
Balance at September 30, 2023	3,577 \$ 1,788 \$ 44,358 \$ 57,082 \$ (4,916) 1,042 \$ (57,066) \$ 54 \$ 41,300						
Balance at March 31, 2023							
Balance at March 31, 2023							
Balance at March 31, 2023							
Balance at January 1, 2024							
Net income attributable to Merck & Co., Inc.							
Other comprehensive loss, net of taxes							
Cash dividends declared on common stock (\$0.77 per share)							
Treasury stock shares purchased							
Share-based compensation plans and other							
Net income attributable to noncontrolling interests							
Balance at March 31, 2024							
Balance at March 31, 2024							
Balance at March 31, 2024							

(\$ and shares in millions except per share amounts)	Nine Months Ended September 30,									
	Common Stock		Other		Accumulated		Treasury Stock		Non-controlling	
	Shares	Par Value	Paid-In Capital	Retained Earnings	Other Comprehensive	Shares	Cost	Interests	Total	
Balance at January 1, 2022	3,577 \$ 1,788 \$ 44,238 \$ 53,696 \$ (4,429)					1,049 \$ (57,109) \$ 73 \$ 38,257				
Net income attributable to Merck & Co., Inc.	—	—	—	11,502	—	—	—	—	—	11,502
Other comprehensive loss, net of taxes	—	—	—	—	(314)	—	—	—	—	(314)
Cash dividends declared on common stock (\$2.07 per share)	—	—	—	(5,270)	—	—	—	—	—	(5,270)
Share-based compensation plans and other	—	—	5	—	—	(5)	351	—	—	356
Net income attributable to noncontrolling interests	—	—	—	—	—	—	—	6	6	6
Distributions attributable to noncontrolling interests	—	—	—	—	—	—	—	(13)	(13)	(13)
Balance at September 30, 2022	3,577 \$ 1,788 \$ 44,243 \$ 59,928 \$ (4,743)					1,044 \$ (56,758) \$ 66 \$ 44,524				
Balance at January 1, 2023	3,577 \$ 1,788 \$ 44,379 \$ 61,081 \$ (4,768)					1,039 \$ (56,489) \$ 67 \$ 46,058				
Net income attributable to Merck & Co., Inc.	—	—	—	1,591	—	—	—	—	—	1,591
Other comprehensive loss, net of taxes	—	—	—	—	(148)	—	—	—	—	(148)

Cash dividends declared on common stock (\$2.19 per share)	—	—	—	(5,590)	—	—	—	—	(5,590)
Treasury stock shares purchased	—	—	—	—	—	9	(953)	—	(953)
Share-based compensation plans and other	—	—	(21)	—	—	(6)	376	—	355
Net income attributable to noncontrolling interests	—	—	—	—	—	—	—	12	12
Distributions attributable to noncontrolling interests	—	—	—	—	—	—	—	(25)	(25)
Balance at September 30, 2023	3,577	\$	1,788	\$	44,358	\$	57,082	\$	(4,916)
									1,042
									\$
									(57,066)
									\$
									54
									\$
									41,300

- 24 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

12.9. Pension and Other Postretirement Benefit Plans

The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:

	Three Months Ended				Nine Months Ended				
	September 30,				September 30,				
	2023	2022	2023	2022					
(\$ in millions)									
(\$ in millions)									
(\$ in millions)	(\$ in millions)	U.S.	International	U.S.	International	U.S.	International	U.S.	International
Service cost	Service cost	\$ 88	\$ 48	\$ 91	\$ 66	\$ 239	\$ 148	\$ 289	\$ 213
Service cost									
Service cost									
Interest cost									
Interest cost									
Interest cost	Interest cost	130	76	123	35	396	225	330	110
Expected return on plan assets	Expected return on plan assets	(182)	(131)	(182)	(93)	(553)	(390)	(576)	(292)
Amortization of unrecognized prior service (credit) cost	—	(6)	(8)	(3)	(1)	5	(24)	(10)	
Net (gain) loss amortization	—	(1)	10	24	—	(2)	122	73	
Expected return on plan assets									
Expected return on plan assets									
Amortization of unrecognized prior service credit									
Amortization of unrecognized prior service credit									
Amortization of unrecognized prior service credit									
Net loss (gain) amortization									
Net loss (gain) amortization									
Net loss (gain) amortization									
Termination benefits									
Termination benefits									
Termination benefits	Termination benefits	1	—	1	—	2	—	2	1
Curtailments	Curtailments	—	—	3	—	5	—	11	—
Curtailments									

Curtailments													
Settlements													
Settlements													
Settlements	Settlements	—	—	79	—	26	—	180	—				
	\$	37	\$	(14)	\$	117	\$	29	\$	114	\$	(14)	\$

The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:

		Three Months Ended September 30,		Nine Months Ended September 30,	
(\$ in millions)	(\$ in millions)	2023	2022	2023	2022
(\$ in millions)	(\$ in millions)				
Service cost	Service cost				
Service cost	Service cost	\$ 8	\$ 11	\$ 24	\$ 36
Interest cost	Interest cost	16	11	47	34
Interest cost	Interest cost				
Expected return on plan assets	Expected return on plan assets				
Expected return on plan assets	Expected return on plan assets	(16)	(21)	(48)	(64)
Amortization of unrecognized prior service credit	Amortization of unrecognized prior service credit	(12)	(14)	(37)	(42)
Amortization of unrecognized prior service credit	Amortization of unrecognized prior service credit				
Net gain amortization	Net gain amortization				
Net gain amortization	Net gain amortization	(11)	(11)	(31)	(32)
Curtailments	Curtailments	—	—	(1)	(1)
	\$	(15)	\$ (24)	\$ (46)	\$ (69)

- 22 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

In connection with restructuring actions (see Note 5.4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement charges resulting in a charge of \$21 million in the third first quarter and first nine months of both 2023 and 2022. These 2023. This partial settlements settlement triggered remeasurements a remeasurement of some of the Company's U.S. pension plans. The third quarter 2023 remeasurement, which was calculated using discount rates and asset values as of September 30, 2023 March 31, 2023, resulted in a net decrease increase of \$34 \$44 million to net pension liabilities and a related adjustment to AOCL. Remeasurements during the first nine months of 2023 also resulted in an increase of \$13 million to net pension liabilities and a related adjustment to AOCL.

The components of net periodic benefit cost (credit) other than the service cost component are included in *Other (income) expense, net* (see Note 13.10), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in *Restructuring costs* if the event giving rise to the termination benefits, curtailment or settlement related to restructuring actions.

- 25 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

13.10. Other (Income) Expense, Net

Other (income) expense, net, consisted of:

		Three Months Ended September 30,		Nine Months Ended September 30,	
(\$ in millions)	(\$ in millions)	2023	2022	2023	2022
Interest income	Interest income	\$ (73)	\$ (40)	\$ (295)	\$ (62)
Interest expense	Interest expense	317	244	836	727
Interest expense					
Interest expense					
Exchange losses	Exchange losses	85	96	208	220
Loss (income) from investments in equity securities, net ⁽¹⁾		33	371	(240)	1,361
Exchange losses					
Exchange losses					
Income from investments in equity securities, net ⁽¹⁾					
Income from investments in equity securities, net ⁽¹⁾					
Income from investments in equity securities, net ⁽¹⁾					
Net periodic defined benefit plan (credit) cost other than service cost					
Net periodic defined benefit plan (credit) cost other than service cost					
Net periodic defined benefit plan (credit) cost other than service cost					
Net periodic defined benefit plan cost	Net periodic defined benefit plan cost	(138)	(60)	(364)	(208)
Other, net	Other, net	(98)	(182)	243	(462)
Other, net					
Other, net					
	\$ 126	\$ 429	\$ 388	\$ 1,576	

⁽¹⁾ Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.

Other, net (as reflected in the table above) in the first **nine** **three** months of 2023 includes a \$572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note **10** **7**).

Interest paid for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** was **\$678 million** **\$217 million** and **\$660 million** **\$208 million**, respectively.

14.11. Income Taxes

The effective income tax rate of **15.5%** **15.9%** for the **third** **first** quarter of **2023** **2024** reflects a **1.6** percentage point unfavorable discrete impact of a charge for the favorable mix acquisition of income and expense. Harpoon for which no tax benefit was recognized. The effective income tax rate of **59.3%** **22.6%** for the first **nine** **months** quarter of **2023** includes reflects a **44.0** **5.5** percentage point combined unfavorable discrete impact of **charges** a charge for the **acquisitions** acquisition of **Prometheus** and **Imago** for which no tax benefits were recognized, as well as higher foreign taxes, the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 (TCJA) on the Company's U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rates of **9.2%** for the third quarter of **2022** and **11.0%** for the first **nine**

months of 2022 reflect the favorable mix of income and expense, as well as the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. benefit was recognized.

The Internal Revenue Service (IRS) is currently conducting examinations of the Company's tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA, Tax Cuts and Jobs Act of 2017. If the IRS disagrees with the Company's transition tax position, it may result in a significant tax liability. The statute of limitations for assessments with respect to the 2019 and 2020 federal return years will expire in June and October of 2024, respectively, unless extended.

15.12. Earnings Per Share

The calculations of earnings per share are as follows:

		Three Months Ended September 30,		Nine Months Ended September 30,	
(\$ and shares in millions except per share amounts)	(\$ and shares in millions except per share amounts)	2023	2022	2023	2022
(\$ and shares in millions except per share amounts)					
(\$ and shares in millions except per share amounts)					
Net Income Attributable to Merck & Co., Inc.					
Net Income Attributable to Merck & Co., Inc.					
Net Income Attributable to Merck & Co., Inc.	Net Income Attributable to Merck & Co., Inc.	\$ 4,745	\$ 3,248	\$ 1,591	\$ 11,502
Average common shares outstanding	Average common shares outstanding	2,537	2,533	2,538	2,531
Average common shares outstanding					
Average common shares outstanding					
Common shares issuable ⁽¹⁾					
Common shares issuable ⁽¹⁾					
Common shares issuable ⁽¹⁾	Common shares issuable ⁽¹⁾	9	9	11	9
Average common shares outstanding assuming dilution	Average common shares outstanding assuming dilution	2,546	2,542	2,549	2,540
Average common shares outstanding assuming dilution					
Average common shares outstanding assuming dilution					
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders					
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders					
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders	Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders	\$ 1.87	\$ 1.28	\$ 0.63	\$ 4.55
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders	Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders	\$ 1.86	\$ 1.28	\$ 0.62	\$ 4.53
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders					
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders					

(1) Issuable primarily under share-based compensation plans.

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

For the **third** first quarter of 2024 and 2023, 3 million and 2022, 6 million and 2 million, respectively, and for the first nine months of 2023 and 2022, 5 million and 5 million 1 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution because the effect would have been antidilutive.

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

16.13. Other Comprehensive Income (Loss)

Changes in each component of other comprehensive income (loss) are as follows:

(\$ in millions)	Three Months Ended September 30,				
	Derivatives	Employee	Foreign Currency	Accumulated Other	
		Benefit	Translation	Comprehensive	Loss
Balance July 1, 2022, net of taxes	\$ 390	\$ (2,465)	\$ (2,252)	\$ (4,327)	
Other comprehensive income (loss) before reclassification adjustments, pretax	682	(294)	(618)		(230)
Tax	(143)	62	50		(31)
Other comprehensive income (loss) before reclassification adjustments, net of taxes	539	(232)	(568)		(261)
Reclassification adjustments, pretax	(254) ⁽¹⁾	77 ⁽²⁾	—		(177)
Tax	53	(31)	—		22
Reclassification adjustments, net of taxes	(201)	46	—		(155)
Other comprehensive income (loss), net of taxes	338	(186)	(568)		(416)
Balance September 30, 2022, net of taxes	\$ 728	\$ (2,651)	\$ (2,820)	\$ (4,743)	
Balance July 1, 2023, net of taxes	\$ 85	\$ (2,483)	\$ (2,502)	\$ (4,900)	
Other comprehensive income (loss) before reclassification adjustments, pretax	247	29	(252)		24
Tax	(52)	(7)	77		18
Other comprehensive income (loss) before reclassification adjustments, net of taxes	195	22	(175)		42
Reclassification adjustments, pretax	(45) ⁽¹⁾	(27) ⁽²⁾	—		(72)
Tax	9	5	—		14
Reclassification adjustments, net of taxes	(36)	(22)	—		(58)
Other comprehensive income (loss), net of taxes	159	—	(175)		(16)
Balance September 30, 2023, net of taxes	\$ 244	\$ (2,483)	\$ (2,677)	\$ (4,916)	

(\$ in millions)	Nine Months Ended September 30,					Three Months Ended March 31,				
	Derivatives	Plans	Foreign	Accumulated	(\$ in millions)	Derivatives	Plans	Employee	Foreign Currency	Accumulated Other
			Employee	Currency				Benefit	Translation	
Balance January 1, 2022, net of taxes	\$ 144	\$ (2,743)	\$ (1,830)	\$ (4,429)						
Other comprehensive income (loss) before reclassification adjustments, pretax	1,233	(125)	(1,001)	107						

Tax	(259)	25	11	(223)
Other comprehensive income (loss) before reclassification adjustments, net of taxes	974	(100)	(990)	(116)
Reclassification adjustments, (1) pretax	(493)	266	—	(227)
Tax	103	(74)	—	29
Reclassification adjustments, net of taxes	(390)	192	—	(198)
Other comprehensive income (loss), net of taxes	584	92	(990)	(314)
Balance September 30, 2022, net of taxes	\$ 728	\$ (2,651)	\$ (2,820)	\$ (4,743)
Balance January 1, 2023, net of taxes	\$ 73	\$ (2,408)	\$ (2,433)	\$ (4,768)
Other comprehensive income (loss) before reclassification adjustments, net of taxes	375	(24)	(288)	63
Tax	Tax	(79)	(4)	35
Other comprehensive income (loss) before reclassification adjustments, net of taxes	296	(28)	(253)	15
Reclassification adjustments, net of taxes	Reclassification adjustments, (1) pretax	(158)	(57)	9
Tax	Tax	33	10	—
Reclassification adjustments, net of taxes	(125)	(47)	9	(163)
Other comprehensive income (loss), net of taxes	171	(75)	(244)	(148)
Balance September 30, 2023, net of taxes	\$ 244	\$ (2,483)	\$ (2,677)	\$ (4,916)
Balance March 31, 2023, net of taxes				
Balance January 1, 2024, net of taxes				
Other comprehensive income (loss) before reclassification adjustments, net of taxes				
Tax				

Other comprehensive income (loss) before reclassification adjustments, net of taxes

Reclassification adjustments, pretax

Tax

Reclassification adjustments, net of taxes

Other comprehensive income (loss), net of taxes

Balance March 31, 2024, net of taxes

(a) Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.

(b) Includes net amortization of prior service cost/credit, cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 12) 9.

- 27 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

17.14. Segment Reporting

The Company's operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.

The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.

The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.

- 28 24 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Sales of the Company's products were as follows:

Three Months Ended March 31,

Three Months Ended March 31,

Three Months Ended March 31,

2024

2024

2024

(\$ in millions)

(\$ in millions)

(\$ in millions)

Pharmaceutical:

Pharmaceutical:

Pharmaceutical:

Oncology

Oncology

Oncology

Keytruda

Keytruda

Keytruda

Alliance revenue-

Lynparza (1)

Alliance revenue-

Lynparza (1)

Alliance revenue-

Lynparza (1)

Alliance revenue-

Lenvima (1)

Alliance revenue-

Lenvima (1)

Alliance revenue-

Lenvima (1)

Welireg

Welireg

Welireg

Alliance revenue-

Reblozyl (2)

Alliance revenue-

Reblozyl (2)

Alliance revenue-

Reblozyl (2)

Vaccines

Vaccines

Vaccines

Gardasil/Gardasil 9

Gardasil/Gardasil 9

Gardasil/Gardasil 9

ProQuad/M-M-R

IV/Varivax

ProQuad/M-M-R

IV/Varivax

ProQuad/M-M-R

IV/Varivax

Vaxneuvance

Vaxneuvance

Vaxneuvance

Rotarix

Rotarix

Rotarix

Pneumovax 23

Pneumovax 23

Pneumovax 23

Hospital Acute Care

Hospital Acute Care

Hospital Acute Care

Bridion

Bridion

Bridion

Prevymis

Prevymis

Prevymis

Difid

Difid

Difid

Zerbaxa

Zerbaxa

Zerbaxa

Noxafil

Noxafil

Noxafil

Cardiovascular

Cardiovascular

Cardiovascular

Alliance revenue-

Adempas/Verquvo (3)

Alliance revenue-

Adempas/Verquvo (3)

Alliance revenue-

Adempas/Verquvo (3)

Adempas

Adempas

Adempas

Virology

Virology

Virology

Lagevrio

Lagevrio

Lagevrio

Isentress/Isentress HD

Isentress/Isentress HD

Isentress/Isentress HD

Delstrigo

Delstrigo

Delstrigo

Pifeltro

Pifeltro

Pifeltro

Neuroscience

Neuroscience

Neuroscience

Belsomra

Belsomra

Belsomra

Immunology

Immunology

Immunology
Simponi
Simponi
Simponi
Remicade
Remicade
Remicade
Diabetes
Diabetes
Diabetes
Januvia
Januvia
Januvia
Janumet
Janumet
Janumet
Other pharmaceutical (4)
Other pharmaceutical (4)
Other pharmaceutical (4)

Total Pharmaceutical
segment sales

Total Pharmaceutical
segment sales

Total Pharmaceutical
segment sales

Animal Health:

Animal Health:

Animal Health:
Livestock
Livestock
Livestock
Companion Animal
Companion Animal
Companion Animal

Total Animal Health
segment sales

Total Animal Health
segment sales

Total segment sales

Total segment sales

Total segment sales

Other (5)

Other (5)

Other (5)

Three Months Ended September 30,

Nine Months Ended September 30,

(\$ in millions)	2023			2022			2023			2022		
	U.S.	Int'l	Total									

Pharmaceutical:

Oncology

<i>Keytruda</i>	\$ 3,795	\$ 2,543	\$ 6,338	\$ 3,331	\$ 2,095	\$ 5,426	\$ 11,142	\$ 7,261	\$ 18,403	\$ 9,307	\$ 6,180	\$ 15,487
Alliance revenue:												
<i>Lynparza</i> (1)	153	146	299	144	140	284	439	445	884	427	397	825
Alliance revenue:												
<i>Lenvima</i> (1)	160	100	260	142	60	202	476	258	734	426	235	660
<i>Welireg</i>	51	3	54	38	—	38	141	6	146	83	—	83
Alliance revenue:												
<i>Reblozyl</i> (2)	43	10	52	32	7	39	108	33	142	87	37	124
Vaccines												
<i>Gardasil/Gardasil 9</i>	838	1,746	2,585	957	1,337	2,294	1,718	5,297	7,015	1,803	3,624	5,428
ProQuad/M-M-R												
<i>IVVarivax</i>	567	146	713	532	136	668	1,435	388	1,823	1,337	379	1,716
<i>RotaTeq</i>	108	48	156	154	102	256	381	203	584	427	218	644
<i>Vaxneuvance</i>	182	33	214	15	1	16	423	65	488	31	1	32
<i>Pneumovax 23</i>	42	98	140	68	63	131	105	223	327	280	177	457
<i>Vaqta</i>	32	37	69	27	36	64	91	60	151	72	62	134
Hospital Acute Care												
<i>Bridion</i>	265	159	424	233	190	423	841	572	1,413	665	579	1,244
<i>Prevymis</i>	70	87	157	49	64	114	186	244	430	136	174	310
<i>Difid</i>	69	5	74	72	6	77	199	16	215	184	12	196
<i>Primaxin</i>	—	41	41	—	63	63	2	173	174	1	185	185
<i>Noxafil</i>	4	47	51	13	49	62	29	138	167	39	141	180
<i>Zerbaxa</i>	29	24	53	24	19	43	86	71	157	64	55	120
Cardiovascular												
Alliance revenue:												
<i>Adempas/Verquvo</i> (3)	96	(4)	92	85	3	88	249	10	259	244	14	258
<i>Adempas</i>	—	65	65	—	57	57	—	189	189	—	181	181
Virology												
<i>Lagevrio</i>	—	640	640	—	436	436	—	1,236	1,236	1,523	3,336	4,859
<i>Isentress/Isentress HD</i>	58	61	119	68	93	161	165	212	377	196	270	466
Neuroscience												
<i>Belsomra</i>	23	35	58	20	42	62	60	117	176	60	139	199
Immunology												
<i>Simponi</i>	—	179	179	—	173	173	—	539	539	—	540	540
<i>Remicade</i>	—	45	45	—	49	49	—	144	144	—	163	163
Diabetes												
<i>Januvia</i>	328	252	581	332	385	717	842	800	1,642	958	1,294	2,252
<i>Janumet</i>	43	211	255	90	327	417	182	755	937	258	1,089	1,347
<i>Other pharmaceutical</i> (4)	197	353	549	194	410	603	540	1,147	1,690	511	1,225	1,736
Total Pharmaceutical												
segment sales	7,153	7,110	14,263	6,620	6,343	12,963	19,840	20,602	40,442	19,119	20,707	39,826
Animal Health:												
<i>Livestock</i>	205	669	874	186	643	829	543	1,987	2,530	521	1,965	2,486
<i>Companion Animal</i>	257	269	526	289	253	542	875	942	1,817	904	929	1,834
Total Animal Health												
segment sales	462	938	1,400	475	896	1,371	1,418	2,929	4,347	1,425	2,894	4,320
<i>Total segment sales</i>	7,615	8,048	15,663	7,095	7,239	14,334	21,258	23,531	44,789	20,544	23,601	44,146
<i>Other</i> (5)	100	199	299	227	398	625	135	561	696	383	925	1,307
	\$ 7,715	\$ 8,247	\$ 15,962	\$ 7,322	\$ 7,637	\$ 14,959	\$ 21,393	\$ 24,092	\$ 45,485	\$ 20,927	\$ 24,526	\$ 45,453

U.S. plus international may not equal total due to rounding.

(1) Alliance revenue for Lynparza and Lenvima represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).

(2) Alliance revenue for Reblozyl represents royalties and, for the first nine months of 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).

(a) Alliance revenue for Adempas/Verquvo represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).

(c) Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

(d) Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by \$173 \$54 million and \$533 \$99 million for the **nine three** months ended **September 30, 2023** **March 31, 2024** and **2022**, **2023**, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the **nine three** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** also includes \$118 \$61 million and \$156 \$51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.

29 25 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by \$3.1 billion \$3.2 billion and \$3.3 billion \$3.1 billion for the three months ended **September 30, 2023** **March 31, 2024** and **2022**, respectively, and \$9.4 billion and \$9.1 billion for the nine months ended **September 30, 2023** and **2022**, **2023**, respectively.

Consolidated sales by geographic area where derived are as follows:

	Three Months Ended
	March 31,
	Three Months Ended
	March 31,
	Three Months Ended
	March 31,
(\$ in millions)	
(\$ in millions)	
(\$ in millions)	
United States	
United States	
United States	
Europe, Middle East and Africa	
Europe, Middle East and Africa	
Europe, Middle East and Africa	
China	
China	
China	
Japan	
Japan	
Japan	
Latin America	
Latin America	
Latin America	
Asia Pacific (other than China and Japan)	
Asia Pacific (other than China and Japan)	
Asia Pacific (other than China and Japan)	
Other	
Other	
Other	

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2023	2022	2023	2022	2022	2022
(\$ in millions)	\$	\$	\$	\$	\$	\$
United States	\$ 7,715	\$ 7,322	\$ 21,393	\$ 20,927		
Europe, Middle East and Africa	3,327	3,286	9,978	11,228		
China	1,694	1,442	5,322	3,957		
Japan	1,081	673	2,514	2,776		
Asia Pacific (other than China and Japan)	781	854	2,475	2,792		
Latin America	895	684	2,298	1,933		
Other	469	698	1,505	1,840		
	\$ 15,962	\$ 14,959	\$ 45,485	\$ 45,453		

A reconciliation of segment profits to *Income Before Taxes* is as follows:

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2023	2022	2023	2022	2022	2022
(\$ in millions)	(\$ in millions)	(\$ in millions)	(\$ in millions)	(\$ in millions)	(\$ in millions)	(\$ in millions)
Segment profits:						
Segment profits:						
Segment profits:	Segment profits:					
Pharmaceutical segment	Pharmaceutical segment	\$ 10,407	\$ 9,590	\$ 29,400	\$ 28,263	
Pharmaceutical segment						
Pharmaceutical segment						
Animal Health segment						
Animal Health segment	Animal Health segment	421	515	1,453	1,672	
Total segment profits	Total segment profits	10,828	10,105	30,853	29,935	
Total segment profits						
Total segment profits						
Other profits						
Other profits						
Other profits	Other profits	190	377	374	831	
Unallocated:	Unallocated:					
Unallocated:						
Interest income						
Interest income						
Interest income	Interest income	73	40	295	62	
Interest expense	Interest expense	(317)	(244)	(836)	(727)	
Interest expense						
Interest expense						
Amortization						
Amortization						
Amortization	Amortization	(562)	(460)	(1,582)	(1,623)	
Depreciation	Depreciation	(401)	(448)	(1,175)	(1,257)	
Depreciation						
Depreciation						

Research and development						
Research and development						
Research and development	Research and development	(3,183)	(4,277)	(20,523)	(9,374)	
Restructuring costs	Restructuring costs	(126)	(94)	(344)	(288)	
Restructuring costs						
Restructuring costs						
Charge for Zetia antitrust litigation settlements						
Charge for Zetia antitrust litigation settlements						
Charge for Zetia antitrust litigation settlements	Charge for Zetia antitrust litigation settlements	—	—	(573)	—	
Other unallocated, net	Other unallocated, net	(882)	(1,416)	(2,554)	(4,628)	
Other unallocated, net						
Other unallocated, net						
		\$ 5,620	\$ 3,583	\$ 3,935	\$ 12,931	

Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred **in by** Merck Research Laboratories, the Company's research and development division that focuses on human health-related activities, or general and administrative expenses **not directly incurred by the segments**, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and **amortization of** purchase accounting adjustments are not allocated to segments.

Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (**losses**) related to third-party manufacturing arrangements.

Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.

- 30 26 -

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Business Developments/Development Transactions

Below is a summary of significant business development activity thus far in **2023**. See Note 2 to the condensed consolidated financial statements for additional information. **2024**.

In **October 2023, March 2024**, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body's immune system to treat patients suffering from cancer and Daiichi Sankyo entered into other diseases, for \$765 million and also incurred \$56 million of transaction costs. Harpoon's lead candidate, MK-6070 (formerly HPN328), is a global development T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and commercialization agreement for three of Daiichi Sankyo's deruxtecan (DXd) antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotag deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy and/or in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of DLL3. The study is also evaluating MK-6070 in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except atezolizumab in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply. Under the terms of the agreement, Merck made upfront payments of \$4.0 billion and will make continuation payments of \$1.5 billion to Daiichi Sankyo and Daiichi Sankyo is eligible to receive future contingent sales-based milestone payments. In conjunction with this transaction, Merck will record an aggregate pretax charge of \$5.5 billion to **Research and development** expenses, or approximately \$1.70 per share, in the fourth quarter of 2023. In addition, Merck will invest in the pipeline assets and incur costs to finance the transaction, resulting in a negative impact to earnings per share (EPS) of approximately \$0.25 in the first 12 months following the close of the transaction.

In June 2023, Merck acquired Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of \$11.0 billion included \$1.2 billion of costs to settle share-based equity awards (including \$700 million to settle unvested equity awards). Prometheus' lead candidate, MK-7240 (formerly PRA023), is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. MK-7240 is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn's disease, and other autoimmune conditions. **SCLC**. The transaction was accounted for as an acquisition of an asset. **asset acquisition**. Merck recorded net assets of \$877 million, including cash of \$368 million, investments of \$296 million, deferred tax assets of \$218 million and other net liabilities of \$5 million \$165 million, as well as a charge of \$10.2 billion \$656

million, or \$0.26 per share, to Research and development expenses or \$4.00 per share, in the first nine months quarter of 2023 2024 related to the transaction. There are no future contingent payments associated with the acquisition.

In February 2023, Merck and Kelun-Biotech (a holding subsidiary entered into a definitive agreement to acquire the aqua business of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship Elanco Animal Health Incorporated (Elanco) for \$1.3 billion in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up cash. The Elanco aqua business to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of \$175 million, which was recorded in Research and development expenses in the first nine months of 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Kelun-Biotech remains eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested \$100 million in Kelun-Biotech's shares in January 2023.

In January 2023, Merck ~~be~~ acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for \$1.35 billion (including payments to settle share-based equity awards) and also incurred approximately \$60 million of transaction costs. Imago's lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition consists of an asset. Merck recorded net assets innovative portfolio of \$219 million, medicines and vaccines, nutraceuticals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a charge research facility in Chile. Upon closing, the acquisition will broaden Animal Health's aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Irvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of \$1.2 billion water treatment products for warm water production, complementing Animal Health's warm water vaccine portfolio. In addition to Research these products, the DNA-based vaccine technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and development expenses in the first nine months of 2023 related to the transaction. There are no future contingent payments associated with the acquisition. Other customary closing conditions. The transaction will be accounted for as a business combination.

Pricing

Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. Accordingly, manufacturers may have reduced prices to pay state Medicaid programs more in rebates than they receive on sales of generic particular products. As a result of this provision, the Company has recognized increased discounts for Januvia (sitagliptin) and patented drugs. In addition, the Company's sales performance Janumet (sitagliptin and metformin HCl) in the first ninethree months of 2023 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. 2024. In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In August 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), announced that Januvia (sitagliptin) will be included in the first year of the IRA's "Drug Price Negotiation Program" (Program). Pursuant to the IRA's Program, discussions with the government will occur in 2023 and will continue in 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA's Program (see Note 10 to the condensed consolidated financial statements). Program. Furthermore, the Biden Administration and

- 31 -

Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company's sales performance in the first three months of 2024 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.

Operating Results

Sales

		Three Months Ended		% Change		Nine Months Ended		% Change	
		September 30,		Excluding		September 30,		Excluding	
		Three Months Ended		Foreign				Foreign	
		March 31,		Exchange				Exchange	
		Three Months Ended							
		March 31,							
		Three Months Ended							
		March 31,							
(\$ in millions)									
(\$ in millions)									
(\$ in millions)	(\$ in millions)	2023	2022	% Change		% Change	2023	2022	% Change
United States	United States	\$ 7,715	\$ 7,322	5	%	Excluding	\$ 21,393	\$ 20,927	2 %
				Foreign		Foreign			Exchange
				Exchange		Exchange			Exchange
United States	United States	\$ 7,715	\$ 7,322	5	%	Excluding	\$ 21,393	\$ 20,927	2 %
				Foreign		Foreign			Exchange
				Exchange		Exchange			Exchange

United States	International	8,247	7,637	8	%	12	%	24,092	24,526	(2)	%	4	%
Total	Total	\$ 15,962	\$ 14,959	7	%	9	%	\$ 45,485	\$ 45,453	—	%	3	%
<hr/>													
<hr/>													

Worldwide sales grew 7% to \$16.0 billion were \$15.8 billion in the third first quarter of 2024, an increase of 9% compared with the first quarter of 2023, or 12% excluding the unfavorable effect of foreign exchange. Approximately 2 percentage points of the negative impact of foreign exchange was due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Global sales growth in the first quarter of 2024 was primarily due to higher sales in the

- 27 -

oncology franchise, largely driven by strong growth of Keytruda (pembrolizumab), and higher Welireg (belzutifan). Higher sales in the vaccines franchise also contributed to revenue growth in the first quarter, primarily attributable to growth increased combined sales of Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and the ongoing launch of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use. Also contributing to revenue growth in the third quarter were higher use, partially offset by lower sales in the virology franchise largely due to Lagevrio RotaTeq (molnupiravir) (Rotavirus Vaccine, Live Oral, Pentavalent) and Pneumovax 23 (pneumococcal vaccine polyvalent). Revenue growth in the third first quarter of 2023 2024 was partially offset by lower sales in the diabetes franchise attributable to Januvia and Janumet (sitagliptin and metformin HCl), lower sales of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent) and lower revenue from third-party manufacturing arrangements.

Worldwide sales were nearly flat in the first nine months of 2023 compared with the corresponding prior year period. Sales performance reflects higher sales in the oncology franchise, largely driven by strong growth of Keytruda, higher sales in the vaccines franchise, primarily attributable to growth of Gardasil 9 and the ongoing launch of Vaxneuvance for pediatric use, as well as higher sales of hospital acute care products, including Bridion (sugammadex) and Prevymis (letermovir). These increases were offset by lower sales in the virology franchise, largely attributable to Lagevrio, as well as lower sales in the diabetes franchise due to Januvia and Janumet, lower sales of Pneumovax 23 (pneumococcal vaccine polyvalent), and lower revenue from third-party manufacturing arrangements.

See Note 17 14 to the condensed consolidated financial statements for details on sales of the Company's products. A discussion of performance for select products in the franchises follows. All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.

Pharmaceutical Segment

Oncology

		Three Months Ended			% Change		Nine Months Ended			% Change	
		September 30,			Excluding		September 30,			Excluding	
		Three Months Ended			Foreign		Three Months Ended			Foreign	
		March 31,			Exchange		March 31,			Exchange	
		Three Months Ended									
		March 31,									
		Three Months Ended									
		March 31,									
(\$ in millions)											
(\$ in millions)											
(\$ in millions)											
(\$ in millions)											
Keytruda		2023			2022		% Change			% Change	
Keytruda		\$ 6,338			\$ 5,426		17 %			Excluding	
Keytruda		\$ 18,403			\$ 15,487		19 %			Foreign	
Keytruda											
Keytruda											
Alliance Revenue -											
Lynparza (1)											
Alliance Revenue -											
Lynparza (1)											

Alliance	Alliance										
Revenue -	Revenue -										
Lynparza ⁽¹⁾	Lynparza ⁽¹⁾	299	284	5	%	6	%	884	825	7	%
Alliance	Alliance										
Revenue -	Revenue -										
Lenvima ⁽¹⁾	Lenvima ⁽¹⁾	260	202	29	%	30	%	734	660	11	%
Alliance Revenue -											
Lenvima ⁽¹⁾											
Alliance Revenue -											
Lenvima ⁽¹⁾											
Welireg											
Welireg											
Welireg	Welireg	54	38	43	%	43	%	146	83	77	%
Alliance	Alliance										
Revenue -	Revenue -										
Reblozyl ⁽²⁾	Reblozyl ⁽²⁾	52	39	35	%	35	%	142	124	14	%
Alliance Revenue -											
Reblozyl ⁽²⁾											

* > 100%

⁽¹⁾ Alliance revenue for Lynparza and Lenvima represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).

⁽²⁾ Alliance revenue for Reblozyl represents royalties and, for the first nine months 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 3 to the condensed consolidated financial statements).

Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for over 35 indications in the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors (including MSI-H/dMMR colorectal cancer 2 tumor-agnostic indications, and endometrial carcinoma), non-small-cell lung cancer (NSCLC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) solid tumors, and urothelial carcinoma including non-muscle invasive bladder cancer. Keytruda is also approved as monotherapy for the adjuvant treatment of certain patients with melanoma, and for certain patients with renal cell carcinoma (RCC) post-surgery. Keytruda is approved for adjuvant treatment following resection and platinum-based chemotherapy for certain patients with NSCLC. Additionally, Keytruda is approved for patients with certain types of resectable NSCLC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Keytruda is also approved for patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, Keytruda has similarly been approved in combination with chemotherapy markets worldwide for the treatment of certain patients with advanced NSCLC, in combination with chemotherapy for certain types of advanced biliary tract cancer, in combination with chemotherapy with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for advanced esophageal cancer, in combination with trastuzumab and chemotherapy for certain patients with advanced gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for

- 32 -

advanced TNBC, in combination with axitinib for advanced RCC, in combination with Lenvima for patients with advanced RCC or certain types of advanced endometrial carcinoma, and in combination with enfortumab vedotin for certain cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma; these indications. The Keytruda clinical development program includes studies across a broad range of cancer types. See "Research and Development Update" below.

Global sales of Keytruda grew 17% and 20% in the third first quarter and first nine months of 2023, respectively. Sales 2024, or 24% excluding the unfavorable effect of foreign exchange. Substantially all of the 4% negative impact of foreign exchange was due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Keytruda sales growth in both periods the first quarter 2024 was primarily driven by higher demand as reflecting the Company continues to launch Keytruda with of multiple new indications globally, globally coupled with continued uptake in existing indications. Sales growth in the U.S. reflects increased uptake across earlier-stage indications including in certain types of non-small-cell lung cancer (NSCLC), high-risk early stage TNBC, early-stage triple-negative breast cancer (TNBC), as well as certain types of RCC and melanoma, renal cell carcinoma (RCC), and higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, NSCLC, TNBC, HNSCC, urothelial, endometrial, microsatellite instability-high (MSI-H) and bladder renal cell cancers, as well as higher pricing. Keytruda sales growth in international markets reflects higher demand predominately for the HNSCC TNBC and RCC metastatic earlier-stage indications, as well as uptake in TNBC head and neck squamous cell carcinoma and RCC earlier-stage metastatic indications, particularly in Europe and Latin America and Japan. America.

Keytruda received the following regulatory approvals thus far in 2023/2024.

Date	Approval
January 2023-2024	U.S. Food and Drug Administration (FDA) approval as a single agent in combination with chemoradiotherapy for adjuvant the treatment following surgical resection and platinum-based chemotherapy for adult of patients with stage IB (T2a \geq 4 cm), II, or IIIA NSCLC, FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-091 KEYNOTE-A18 trial.
March 2023- January 2024	FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and hepatocellular carcinoma (HCC) secondary to hepatitis B who have no satisfactory alternative treatment options. received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials, KEYNOTE-394 trial.
April 2023- February 2024	FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.
June 2023	Japan's Ministry of Health, Labor and Welfare (MHLW) approval for the treatment of patients with relapsed or refractory PMBCL, based on the KEYNOTE-170 and the KEYNOTE-A33 studies.
August 2023	European Commission (EC) approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1, based on the KEYNOTE-811 trial.
October 2023	EC approval as a monotherapy for the adjuvant treatment of adults with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy, based on the KEYNOTE-091 trial.
October 2023	FDA approval for the treatment of patients with resectable (tumors \geq 4cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery, based on the KEYNOTE-671 trial.
October 2023	FDA full approval for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-913 and KEYNOTE-017 trials.
October 2023	FDA China's National Medical Products Administration approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, carcinoma, based on the KEYNOTE-966 trial.
March 2024	European Commission (EC) approval in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable NSCLC at high risk of recurrence in adults, based on the KEYNOTE-671 trial.

The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of *Keytruda*. Under the terms of the more significant of these agreements, Merck paid a royalty of 6.5% on worldwide sales of *Keytruda* through December 2023 to one third party; this royalty declined to 2.5% in 2024 and will continue through 2026, terminating thereafter. The Company pays an additional 2% royalty on worldwide sales of *Keytruda* to another third party, the

- 28 -

termination date of which varies by country; this royalty will expire in the U.S. in September 2024 and on varying dates in major European markets in the second half of 2025. The royalty expenses are included in *Cost of sales*.

Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements). *Lynparza* is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to *Lynparza* increased 5% 6% in the third first quarter of 2023 2024 primarily driven by higher pricing demand in the U.S. and higher demand certain international markets, particularly in Latin America. Alliance revenue related to *Lynparza* grew 7% in the first nine months of 2023 primarily driven by higher pricing and demand in the U.S., as well as higher demand in several international markets. In May 2023, the FDA approved *Lynparza* in combination with abiraterone and prednisone or prednisolone for the treatment of certain adult patients with deleterious or suspected deleterious *BRCA*-mutated (*BRCA*m) metastatic castration-resistant prostate cancer (mCRPC), based on the PROpel trial. In August 2023, Japan's MHLW approved *Lynparza* in combination with abiraterone and prednisolone for treatment of adult patients with *BRCA*m mCRPC with distant metastasis, based on the PROpel trial.

Lenvima (lenvatinib) is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements). *Lenvima* is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with *Keytruda* for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to *Lenvima* grew 29% 10% in the third first quarter of 2023 largely 2024 primarily reflecting higher demand in the U.S. and certain international markets, as well as the timing of purchases in China. Alliance revenue related to *Lenvima* grew 11% in the first nine months of 2023 largely reflecting higher demand in the U.S. and Europe, partially offset by lower demand in China.

Sales of *Welireg* (beluzutifan), for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors grew 43% and 77% certain adult patients with previously treated advanced RCC, more than doubled in the third first quarter and first nine months of 2023, respectively. Sales growth in both periods is 2024 due to continued uptake higher demand in the U.S. following launch in 2021. In September 2023, the FDA accepted and granted priority review for a

- 33 -

supplemental new drug application (NDA) seeking approval for *Welireg* for the treatment of adult patients with VHL disease-associated tumors and uptake in a supplemental indication approved by the FDA in December 2023 for previously treated advanced RCC. *Welireg* is under review in the European Union (EU) for the treatment of previously treated advanced RCC following immune checkpoint

and anti-angiogenic therapies. The supplemental NDA is based on data from the LITESPARK-005 trial. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date clinical trial and for the treatment of January 17, 2024. VHL disease based on the LITESPARK-004 clinical trial.

Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS) (see Note 3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Alliance revenue related to this collaboration consists (consisting of royalties and, for royalties) increased 66% in the first nine months quarter of 2022, also includes the receipt of a regulatory approval milestone payment of \$20 million. Alliance revenue increased 35% and 14% in the third quarter and first nine months of 2023, respectively, 2024 due to strong underlying sales performance. The increase in alliance revenue in the first nine months of 2023 was partially offset by the receipt of the regulatory approval milestone in 2022 as noted above.

Vaccines

		Three Months Ended			% Change		Nine Months Ended			% Change	
		September 30,			Excluding		September 30,			Excluding	
		Three Months Ended			Foreign					Foreign	
		March 31,			Exchange					Exchange	
		Three Months Ended									
		March 31,									
		Three Months Ended									
		March 31,									
(\$ in millions)											
(\$ in millions)											
(\$ in millions)	(\$ in millions)	2023	2022	% Change		% Change	2023	2022	% Change		% Change
Gardasil/Gardasil 9	Gardasil/Gardasil 9	\$ 2,585	\$ 2,294	13 %	Excluding	Foreign	\$ 7,015	\$ 5,428	29 %	Excluding	Foreign
					Exchange					Exchange	
Gardasil/Gardasil 9											
Gardasil/Gardasil 9											
ProQuad											
ProQuad											
ProQuad	ProQuad	267	264	1 %	1 %	678	640	6 %	6 %	6 %	6 %
M-M-R II	M-M-R II	122	124	(2) %	(4) %	329	330	— %	(1) %	(1) %	
M-M-R II											
M-M-R II											
Varivax	Varivax	325	280	16 %	15 %	816	746	9 %	10 %	10 %	
Varivax											
Varivax											
Vaxneuvance											
Vaxneuvance											
Vaxneuvance											
RotaTeq	RotaTeq	156	256	(39) %	(39) %	584	644	(9) %	(8) %	(8) %	
Vaxneuvance		214	16	*	*	488	32	*	*	*	
RotaTeq											
RotaTeq											
Pneumovax 23	Pneumovax 23	140	131	6 %	4 %	327	457	(28) %	(27) %	(27) %	
Pneumovax 23											
Pneumovax 23											

* > 100%

Combined worldwide sales of Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 13% and 29% 14% in the third first quarter and first nine months of 2023, respectively, driven 2024 primarily by due to strong demand, outside of the U.S., particularly in China, due in part to continued uptake which also benefited from the timing of the expanded indication of Gardasil 9 for girls and women 9 to 45 years of age. Sales growth in both periods was partially offset by lower sales in the U.S. due to shipments, as well as public sector buying patterns partially offset by in the U.S., and higher pricing and demand, pricing.

The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on sales of Gardasil/Gardasil 9 in the U.S. to one third party (this royalty expires in December 2028); Merck paid an additional 7% royalty on worldwide sales of Gardasil/Gardasil 9 to another third party, which expired in December 2023. The royalty expenses are included in Cost of sales.

Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, were nearly flat in the third quarter of 2023 compared with the third quarter of 2022. Worldwide sales of ProQuad increased 6% grew 8% in the first nine months quarter of 2023 2024 primarily reflecting

higher pricing in the U.S. and higher demand in certain ex-U.S. markets.

Worldwide sales of M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, were nearly flat in both the third first quarter and first nine months of 2023 compared with the corresponding prior year periods. 2024.

Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), increased 16% 11% in the third first quarter of 2023 2024 primarily attributable to higher pricing and demand in the U.S. and higher sales in Latin America due in part to the timing of government tenders.

Worldwide sales of Vaxneuvance, a vaccine to help protect against invasive pneumococcal disease, more than doubled in the first quarter of 2024 primarily reflecting continued uptake in the pediatric indication in the U.S. and Europe, as well as higher demand in Latin America. Global sales of Varivax grew 9% new market launches. Sales growth in the first nine months U.S. also reflects the beneficial impact of 2023 largely due to higher pricing and demand in the U.S., as well as higher demand in the Asia Pacific region, partially offset by lower demand in Latin America public sector buying patterns.

29

Global sales of RotaTeq, a vaccine to help protect against rotavirus gastroenteritis in infants and children, declined 39% 27% in the third first quarter of 2023 and decreased 9% in first nine months of 2023 2024 primarily due to public sector buying patterns lower sales in the U.S., China reflecting first quarter 2023 inventory stocking, as well as lower sales in China reflecting the continued buy-out of first quarter 2023 inventory stocking.

Worldwide sales of Vaxneuvance, a vaccine to help prevent invasive pneumococcal disease, increased to \$214 million and \$488 million in the third quarter and first nine months of 2023, respectively, primarily U.S. due to continued uptake in the pediatric indication in the U.S. and launches in European markets. public sector buying patterns.

Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, grew 6% in the third quarter of 2023 primarily reflecting higher demand in certain ex-U.S. markets that was largely offset by lower demand in the U.S. Global sales of Pneumovax 23 declined 28% 36% in the first nine months quarter of 2023 2024 largely due to lower demand in the U.S., partially offset by higher demand in several ex-U.S. markets. Lower demand for Pneumovax 23 in as the U.S. is being driven by the continued market shift has shifted toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices in 2021. The Company expects the decline in U.S. sales of Pneumovax 23 to continue.

34

Hospital Acute Care

		Three Months Ended			% Change		Nine Months Ended			% Change	
		September 30,			Excluding		September 30,			Excluding	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange		September 30,			Exchange	
		Three Months Ended			Foreign		September 30,			Foreign	
		March 31,			Exchange						

Worldwide sales of *Bridion* (sugammadex), for the reversal of two types of neuromuscular blocking agents used during surgery, were essentially flat in the third first quarter of 2023 reflecting higher demand in the U.S., due in part to *Bridion*'s growing market share among neuromuscular blockade reversal agents, offset by lower demand in certain ex-U.S. markets due to generic competition, particularly in Europe, the EU, partially offset by higher demand in the U.S. The patent that provided market exclusivity for *Bridion* in the European Union (EU) EU expired in July 2023. Accordingly, the Company is experiencing sales declines of *Bridion* in these markets and expects the declines to continue. Global The patent that provided market exclusivity for *Bridion* in Japan expired in January 2024; the Company anticipates sales of *Bridion* grew 14% in the first nine months of 2023 primarily due to higher demand and pricing Japan will decline in the U.S. future periods.

Worldwide sales of *Prevymis* (letermovim), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in certain high risk adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant grew 38% and 39% in the third quarter and first nine months of 2023, respectively, largely due to higher demand in the U.S. and Europe, as well as continued uptake from the 2022 launch in China. In June 2023, the FDA approved a new indication for *Prevymis* for prophylaxis of CMV disease in certain high risk adult recipients of a kidney transplant, recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) following a priority review. In October 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of *Prevymis* for this new indication. The CHMP's recommendation will be reviewed by the EC for marketing authorization grew 35% in the EU first quarter of 2024 largely due to higher global demand, particularly in the U.S. and a final decision is expected later in 2023, China.

Cardiovascular

	Three Months Ended			% Change		Nine Months Ended			% Change	
	September 30,			Excluding		September 30,			Excluding	
	Three Months Ended			Foreign					Foreign	
	March 31,			Exchange					Exchange	
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
(\$ in millions)	(\$ in millions)		2023	2022	% Change	(\$ in millions)	(\$ in millions)		2023	2022
Alliance Revenue -						Alliance Revenue -				
Adempas/						Adempas				
Verquvo (1)	\$	92	\$	88	5 %	Verquvo (1)	\$	259	\$	258
(\$ in millions)										
(\$ in millions)										
Alliance Revenue -						Alliance Revenue -				
Adempas/Verquvo (1)						Adempas/Verquvo (1)				
Alliance Revenue -						Alliance Revenue -				
Adempas/Verquvo (1)						Adempas/Verquvo (1)				
Adempas	Adempas	65	57	15 %	11 %	Adempas	Adempas	189	181	5 %
Adempas										
Adempas										

(1) Alliance revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).

Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension (PAH) and chronic pulmonary hypertension. hypertension (PH). Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration in the third first quarter and first nine months of 2023 2024 was relatively consistent nearly flat compared with the corresponding prior year periods. period. Revenue also includes sales of Adempas and Verquvo in Merck's marketing territories. Sales of Adempas in Merck's marketing territories grew 15% and 5% 18% in the third first quarter and first nine months of 2023, respectively, 2024 primarily due to higher demand.

In March 2024, the FDA approved *Winrevair* (sotatercept-csrk) for the treatment of adults with PAH (World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The approval is based on the STELLAR trial. *Winrevair* is the subject of a licensing agreement with Bristol-Myers Squibb Company (BMS) and Merck will pay 22% royalties on sales of *Winrevair* in the PH field to BMS.

Virology

	Three Months Ended			% Change		Nine Months Ended			% Change	
	September 30,			Excluding		September 30,			Excluding	
	Three Months Ended			Foreign					Foreign	
	March 31,			Exchange					Exchange	
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									
	Three Months Ended									
	March 31,									

(\$ in millions)										
(\$ in millions)										
(\$ in millions)	(\$ in millions)	2023			2022			% Change		% Change
		\$	640		\$	436		47	%	
Lagevrio	Lagevrio							Excluding		
								Foreign		
								Exchange		
Isentress/Isentress HD	Isentress/Isentress HD	119			161		(27)	%	(27)	%
									377	
									466	
									(19)	%
									(17)	%
Lagevrio										
Lagevrio										

Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback Biotherapeutics LP (Ridgeback) (see Note 3 to the condensed consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, *Lagevrio* has since received multiple additional authorizations worldwide. Sales of *Lagevrio* grew 47% in the third quarter of 2023 primarily due to higher demand in Japan, partially offset by lower demand in Australia and the nonrecurrence of sales in the UK. Sales of *Lagevrio* declined 75% 11% in the first nine months quarter of 2023 2024 primarily due to lower demand in certain markets in the Asia Pacific region, partially offset by sales of *Lagevrio* in the U.S. and the UK in the first nine months of 2022 that did not recur in 2023, coupled with lower higher demand in Japan and Australia. The Company expects full-year 2023 *Lagevrio* sales to be approximately \$1.3 billion. In April 2023, Japan's MHLW granted full approval for *Lagevrio*. *Lagevrio* was previously granted Special Approval for Emergency in Japan in December 2021, Japan.

Global combined sales of *Isentress/Isentress HD* (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 27% and 19% in the third quarter and first nine months of 2023, respectively, primarily due to competitive pressure in Europe and the U.S. The patent that provided market exclusivity for

- 35 30 -

Isentress/Isentress HD Immunology

(\$ in millions)										
(\$ in millions)										
(\$ in millions)	(\$ in millions)	2024			2023			% Change		% Change
		\$	184		\$	180		2 %	1 %	
Simponi										
Remicade								39	51	(24)%
										(21)%

Simponi in the EU expired in July 2023. Accordingly, (golimumab) and *Remicade* (infliximab) are treatments for certain inflammatory diseases that the Company is experiencing sales declines of *Isentress/Isentress HD* markets in Europe, Russia and Türkiye. The Company's marketing rights with respect to these markets and expects the declines products will revert to continue. The Company also expects competitive pressure for *Isentress/Isentress HD* in the U.S. to continue, Johnson & Johnson Innovative Medicine on October 1, 2024.

Diabetes

(\$ in millions)									
(\$ in millions)									
(\$ in millions)	(\$ in millions)	Three Months Ended			Nine Months Ended			% Change	
		September 30,			September 30,			Excluding	
Januvia/Janumet	Januvia/Janumet							Foreign	
								Exchange	
Januvia/Janumet	Januvia/Janumet								
Januvia/Janumet	Januvia/Janumet								

Worldwide combined sales of *Januvia* and *Janumet*, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 26% and 28% 24% in the third first quarter of 2024 primarily due to lower sales in the U.S., largely reflecting lower pricing and first nine months of 2023, respectively, primarily reflecting lower demand due to competitive pressures, as well as the ongoing

impact of the loss of exclusivity in most markets in Europe and the Asia Pacific region, as well as in Canada, coupled with lower demand and, for the year-to-date period, lower pricing Canada.

The American Rescue Plan Act enacted in the U.S. due in 2021 included a provision that eliminated the statutory cap on rebates drug manufacturers pay to competitive pressures. Medicaid beginning in January 2024. Accordingly, manufacturers may have to pay state Medicaid programs more in rebates than they receive on sales of particular products. As a result of this provision, the Company has recognized increased discounts for Januvia and Janumet in the first quarter of 2024. In August 2023, the U.S. Department of HHS, through the CMS, announced that Januvia would be included in the first year of the IRA's Program. Pursuant to the IRA's Program, discussions with the government occurred in 2023 and will continue in 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA's Program.

While the key U.S. patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note 10 to the condensed consolidated financial statements), the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although a non-automatically substitutable form of sitagliptin that differs from the form in the Company's sitagliptin products has been approved by the FDA. As a result of competitive pressures, the Company anticipates pricing and volume declines for Januvia and Janumet in the U.S. for the remainder of 2023 and thereafter. In August 2023, the U.S. Department of HHS, through the CMS, announced that Januvia will be included in the first year of the IRA's Program. Pursuant to the IRA's Program, discussions with the government will occur in 2023 and 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA's Program (see Note 10 to the condensed consolidated financial statements). 2024.

The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Exclusivity for Janumet was lost in other European countries in April 2023. Accordingly, the Company is experiencing sales declines in these markets and expects the declines to continue. While the Company lost market exclusivity for Januvia in China in 2022 with the launch of a generic equivalent product and an additional generic equivalent product was launched in the second quarter of 2023, the impact on sales for full-year 2023 is expected to be modest. Although several generic Generic equivalents of Janumet have been approved in China, none have launched, and the Company expects it is unlikely that any will launch prior to December 2023.

Combined sales of Januvia and Janumet have also launched in Europe, China and the U.S. represented 10%, 14% and 40%, respectively, of total combined Januvia and Janumet sales for the first nine months of 2023. China.

In response to a request from a regulatory authority in 2022, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug's manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities' interim acceptable NTTP limits for continuing distribution of product to the market. The Company has made significant progress in reducing the level of nitrosamines in its sitagliptin-containing medicines and does not anticipate product shortages at this time, subject to regulatory approvals for submitted changes.

Animal Health Segment

		Three Months Ended			% Change		Nine Months Ended			% Change	
		September 30,			Excluding		September 30,			Excluding	
		Three Months Ended			Foreign					Foreign	
		March 31,			Exchange					Exchange	
		Three Months Ended									
		March 31,									
		Three Months Ended									
		March 31,									
		(\$ in millions)									
		(\$ in millions)									

of 2023, respectively, primarily 2024 due to fewer vet visits in the U.S., partially offset by higher pricing. Sales of the Bravecto (fluralaner) parasiticide, a line of oral and topical parasitic control products, were \$235 million for the third quarter of 2023, representing a decline of 3% compared with the third quarter of 2022. Sales of Bravecto products were \$875 million \$332 million for the first nine months quarter of 2023, 2024, representing growth of 1% 6% compared with the corresponding prior year period, or 3% 7% excluding the unfavorable effect of foreign exchange.

In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco for \$1.3 billion in cash. See "Business Development Transactions" above for additional information related to this transaction.

- 3631 -

Costs, Expenses and Other

		Three Months Ended				Nine Months Ended			
		September 30,				September 30,			
		Three Months Ended				Three Months Ended			
		March 31,				March 31,			
		Three Months Ended				March 31,			
		(\$ in millions)							
		(\$ in millions)							
(\$ in millions)	(\$ in millions)	2023	2022	% Change		2023	2022	% Change	
Cost of sales	Cost of sales	\$ 4,264	\$ 3,934	8	%	\$ 12,214	\$ 13,530	(10)	%
Cost of sales									
Cost of sales									
Selling, general and administrative									
Selling, general and administrative									
Selling, general and administrative	Selling, general and administrative	2,519	2,520	—	%	7,700	7,355	5	%
Research and development	Research and development	3,307	4,399	(25)	%	20,904	9,773	*	
Research and development									
Research and development									
Restructuring costs									
Restructuring costs									
Restructuring costs	Restructuring costs	126	94	34	%	344	288	19	%
Other (income) expense, net	Other (income) expense, net	126	429	(71)	%	388	1,576	(75)	%
		\$ 10,342	\$ 11,376	(9)	%	\$ 41,550	\$ 32,522	28	%
Other (income) expense, net									
Other (income) expense, net									
		\$							
		\$							
		\$							

* > 100%

Cost of Sales

Cost of sales increased 8% in the third quarter of 2023 and declined 10% in the first nine months quarter of 2023 compared with the corresponding prior year periods. Cost of sales includes \$348 million and \$244 million in the third quarter of 2023 and 2022, respectively, and \$762 million and \$2.6 billion in the first nine months of 2023 and 2022, respectively, related to sales of Lagevrio, which is being developed in a collaboration with Ridgeback. Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and

licensing arrangements, which totaled \$552 million \$462 million and \$445 million \$532 million in the **third** first quarter of 2024 and 2023, and 2022, respectively, and \$1.6 billion in both the first nine months of 2023 and 2022, respectively. Amortization expense in the **third** first quarter of 2023 includes \$81 \$72 million of cumulative catch-up amortization related to Merck's collaboration with Eisai. Amortization expense in the first nine months of 2023 and 2022 includes \$154 million and \$250 million, respectively, of cumulative catch-up amortization related to Merck's collaborations with Eisai and AstraZeneca, respectively. See Note 3 to the condensed consolidated financial statements for more information on Merck's collaborative arrangements. Also included in cost of sales are expenses associated with restructuring activities, which amounted to \$33 million \$116 million and \$54 million in the third quarter of 2023 and 2022, respectively, and \$94 million and \$167 million \$29 million in the first nine months quarter of 2024 and 2023, and 2022, respectively, including primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in *Restructuring costs* as discussed below.

Gross margin was 73.3% 77.6% in the **third** first quarter of 2023 2024 compared with 73.7% 72.9% in the **third** first quarter of 2022 2023. The gross margin **decline improvement** was primarily due to the **unfavorable impacts favorable effects** of product mix (including lower royalty rates related to Keytruda and Gardasil/Gardasil 9 sales), foreign exchange **higher Lagevrio sales** (which **have a low gross margin**) and **higher lower** amortization of intangible assets, partially offset by **lower revenue from third-party manufacturing arrangements** (which **have a low gross margin**), **lower manufacturing-related higher restructuring costs** and **the favorable effect of product mix**. Gross margin was 73.1% in the first nine months of 2023 compared with 70.2% in the first nine months of 2022. The gross margin improvement primarily reflects the favorable impacts of **lower Lagevrio sales**, **lower revenue from third-party manufacturing arrangements**, **lower manufacturing-related costs** and **product mix**, partially offset by the **unfavorable impact of foreign exchange**, **inventory write-offs**.

Selling, General and Administrative

Selling, general and administrative (SG&A) expenses were **nearly flat** in the **third** first quarter of 2023 compared with the third quarter of 2022 reflecting higher promotional spending that was offset by lower administrative costs. SG&A expenses rose 5% in the first nine months of 2023 2024 primarily due to higher administrative costs, **including compensation and benefit costs**, as well as **increased promotional spending and higher selling costs**, partially **largely** offset by **lower acquisition-related costs** promotional spending, reflecting the prioritization of spending on key growth products, and the favorable effect of foreign exchange.

Research and Development

Research and development (R&D) expenses declined 25% 7% in the **third** first quarter of 2023 2024 primarily due to **lower charges recorded for business development transactions**, which included a \$656 million charge for the acquisition of Harpoon in 2022 the first quarter of 2024, compared with charges of \$1.2 billion for **intangible asset impairments** coupled the acquisition of Imago and \$175 million for a license and collaboration agreement with **lower upfront and option payments** Kelun-Biotech in 2023 for collaborations and licensing agreements, the first quarter of 2023. The decline in **R&D expenses** was partially offset by higher compensation and benefit costs, in 2023 (reflecting in part increased headcount), clinical development spending, and higher investments in discovery research and early drug development as well as higher clinical development spending. R&D expenses were \$20.9 billion in the first nine months quarter of 2023 compared with \$9.8 billion in the first nine months of 2022. The increase was primarily due to a \$10.2 billion charge for the acquisition of Prometheus, a \$1.2 billion charge for the acquisition of Imago, higher compensation and benefit costs, higher investments in discovery research and early drug development, as well as increased clinical development spending. The increase in R&D expenses in the first nine months of 2023 was partially offset by charges recorded in 2022 for **intangible asset impairments**, as well as **lower upfront and option payments** in 2023 related to collaborations and licensing arrangements. 2024.

R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company's research and development division that focuses on human health-related activities, which were \$2.3 billion \$2.4 billion and \$2.0 billion for the third quarter of 2023 and 2022, respectively, and \$6.6 billion and \$5.6 billion \$2.1 billion for the first nine months quarter of 2023 2024 and 2022 2023, respectively. Also included in R&D expenses are Animal Health research costs, **upfront payments for collaboration and licensing costs**, **agreements**, charges for transactions accounted for as asset acquisitions (including the charges for the Harpoon and Imago acquisitions as noted above), and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately \$1.0 billion \$1.6 billion and \$1.5 billion for the third quarter of 2023 and 2022, respectively, and \$14.3 billion and \$3.2 billion \$2.2 billion for the first nine months of 2023 and 2022, respectively.

- 37 -

The decline in these non-MRL R&D expenses in the third quarter of 2024 and 2023, largely reflects \$690 million of upfront and option payments in the aggregate made in 2022 for collaborations and licensing agreements with Orion Corporation (Orion), Moderna, Inc. (Moderna) and Orna Therapeutics (Orna). The increase in these non-MRL R&D expenses in the first nine months of 2023 was largely attributable to a \$10.2 billion charge for the acquisition of Prometheus (as noted above), a \$1.2 billion charge for the acquisition of Imago (as noted above) and a \$175 million charge for a license and collaboration agreement with Kelun-Biotech, partially offset by the \$690 million of charges in 2022 for the transactions with Orion, Moderna and Orna. See Note 2 to the condensed consolidated financial statements for additional information related to business development activity. Additionally, R&D expenses in the third quarter and first nine months of 2022 include \$887 million of **intangible asset impairment charges** largely related to nemtibrutinib. See Note 8 to the condensed consolidated financial statements for more information on the **intangible asset impairment charges**, respectively.

Restructuring Costs

In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company's Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately \$4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company expects to record charges of approximately \$800 million in 2024 related to the 2024 Restructuring Program. The Company anticipates the actions under the 2024 Restructuring Program will result in cumulative annual net cost savings of approximately \$750 million by the end of 2031.

In 2019, Merck approved a global restructuring program (Restructuring (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company's manufacturing and supply network, as well as reducing its global real estate

- 32 -

footprint. The actions contemplated under the 2019 Restructuring Program are expected to be substantially completed by the end of 2023 with and, as of January 1, 2024, any remaining activities are now being accounted for as part of the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately \$4.0 billion. Merck expects to record charges of approximately \$650 million for the full year of 2023 related to the 2024 Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately \$900 million by the end of 2023.

Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were \$126 million \$123 million and \$94 million for the third quarter of 2023 and 2022, respectively, and \$344 million and \$288 million \$67 million for the first nine months quarter of 2023 2024 and 2022, 2023, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included Other expenses in restructuring Restructuring costs are asset abandonment, include facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.

Additional costs associated with the Company's restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of \$199 million \$246 million and \$175 million \$97 million in the third first quarter of 2023 2024 and 2022, respectively, and \$532 million and \$559 million for the first nine months of 2023, and 2022, respectively, related to restructuring program activities (see Note 54 to the condensed consolidated financial statements).

Other (Income) Expense, Net

Other (income) expense, net, was \$126 million \$33 million of income in the first quarter of 2024 compared with \$89 million of expense in the third first quarter of 2023 compared with \$429 million of expense in the third quarter of 2022, 2023. The favorability was primarily due to lower losses from investments in equity securities. Other (income) expense, net, was \$388 million of expense for the first nine months of 2023 compared with \$1.6 billion of expense for the first nine months of 2022, primarily due to net unrealized gains from investments in equity securities recorded in 2023 compared with net unrealized losses recorded in 2022, and lower pension settlement costs, partially offset by a \$572.5 million charge in 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 107 to the condensed consolidated financial statements), partially offset by lower income from investments in equity securities and higher interest expense in 2024.

For details on the components of Other (income) expense, net, see Note 13 10 to the condensed consolidated financial statements.

Segment Profits		Segment Profits		Three Months Ended		Nine Months Ended	
Segment Profits				September 30,		September 30,	
Segment Profits				2023	2022	2023	2022
(\$ in millions)	(\$ in millions)						
(\$ in millions)	(\$ in millions)						
(\$ in millions)	(\$ in millions)						
Pharmaceutical segment profits							
Pharmaceutical segment profits							
Pharmaceutical segment profits	Pharmaceutical segment profits	\$	10,407	\$	9,590	\$	29,400
Animal Health segment profits	Animal Health segment profits		421		515		1,453
Animal Health segment profits							
Animal Health segment profits							
Other	Other						
Other	Other						
Other	Other						
Income Before Taxes	Income Before Taxes	\$	5,620	\$	3,583	\$	3,935
Income Before Taxes							
Income Before Taxes							

Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income

related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in "Other" in the above table. Also included in "Other" are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.

Pharmaceutical segment profits grew 9% and 4% in the third quarter and first nine months of 2023, respectively, 2024 primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits declined 18% and 13% in the third quarter and first nine months of 2023, respectively, 2024 reflecting higher manufacturing production costs, higher inventory write-offs, increased administrative and promotional costs, as well as the unfavorable effect of foreign exchange.

Taxes on Income Taxes

The effective income tax rate of 15.5% for the third quarter of 2023 reflects a 1.6 percentage point unfavorable discrete impact of a charge for the favorable mix acquisition of income and expense. Harpoon for which no tax benefit was recognized. The effective income tax rate of 22.6% for the first nine months of 2023 includes reflects a 5.5 percentage point combined unfavorable discrete impact of charges a charge for the acquisitions acquisition of Prometheus and Imago for which no tax benefits were recognized, as well as higher foreign taxes, benefit was recognized.

While many jurisdictions in which Merck operates have adopted the global minimum tax provision of the Organisation for Economic Co-operation and Development (OECD) Pillar 2, effective for tax years beginning in January 2024, the Company anticipates there will be a reduced impact to its 2024 tax rate due to the accounting for the tax effects of intercompany transactions. The Company expects the impact of the R&D capitalization global minimum tax will increase its tax rate to a greater extent in 2025 and thereafter. Also, in the event that the provision of the Tax Cuts and Jobs Act of 2017 on requiring capitalization and amortization of R&D expenses for tax purposes is repealed along the Company's lines recently proposed in the Tax Relief for American Families and

- 33 -

Workers Act of 2024, the Company will again be able to realize the benefit of U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The R&D expenses as incurred but expects no material impact to its effective income tax rates of 9.2% for the third quarter of 2022 and 11.0% for the first nine months of 2022 reflect the favorable mix of income and expense, as well as the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate.

Non-GAAP Income and Non-GAAP EPS

Non-GAAP income and non-GAAP EPS are alternative views of the Company's performance that Merck is providing because management believes this information enhances investors' understanding of the Company's results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance.

Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management's annual compensation, is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).

A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:

		Three Months Ended		Nine Months Ended	
		September 30,		September 30,	
(\$ in millions except per share amounts)		Three Months Ended		Three Months Ended	
		September 30,		September 30,	
(\$ in millions except per share amounts)	(\$ in millions except per share amounts)	Three Months Ended		Three Months Ended	
(\$ in millions except per share amounts)	(\$ in millions except per share amounts)	September 30,		September 30,	
Income before taxes as reported under GAAP	Income before taxes as reported under GAAP	\$ 5,620	\$ 3,583	\$ 3,935	\$ 12,931
Income before taxes as reported under GAAP					
Income before taxes as reported under GAAP					
Increase (decrease) for excluded items:					
Increase (decrease) for excluded items:					
Increase (decrease) for excluded items:	Increase (decrease) for excluded items:				
Acquisition- and divestiture-related costs	Acquisition- and divestiture-related costs	555	1,344	1,643	2,512
Acquisition- and divestiture-related costs					

Acquisition- and divestiture-related costs					
Restructuring costs	Restructuring costs	199	175	532	559
Loss (income) from investments in equity securities, net		17	350	(218)	1,268
Restructuring costs					
Restructuring costs					
Income from investments in equity securities, net					
Income from investments in equity securities, net					
Income from investments in equity securities, net					
Other items:					
Other items:					
Other items:	Other items:				
Charge for Zetia antitrust litigation settlements	Charge for Zetia antitrust litigation settlements	—	—	573	—
Charge for Zetia antitrust litigation settlements					
Charge for Zetia antitrust litigation settlements					
Non-GAAP income before taxes					
Non-GAAP income before taxes					
Non-GAAP income before taxes	Non-GAAP income before taxes	6,391	5,452	6,465	17,270
Income tax provision as reported under GAAP	Income tax provision as reported under GAAP	870	330	2,332	1,423
Income tax provision as reported under GAAP					
Income tax provision as reported under GAAP					
Estimated tax benefit on excluded items (1)					
Estimated tax benefit on excluded items (1)					
Estimated tax benefit on excluded items (1)	Estimated tax benefit on excluded items (1)	89	414	350	965
Non-GAAP income tax provision	Non-GAAP income tax provision	959	744	2,682	2,388
Non-GAAP income tax provision					
Non-GAAP net income					
Non-GAAP net income	Non-GAAP net income	5,432	4,708	3,783	14,882
Less: Net income attributable to noncontrolling interests as reported under GAAP	Less: Net income attributable to noncontrolling interests as reported under GAAP	5	5	12	6
Less: Net income attributable to noncontrolling interests as reported under GAAP					
Non-GAAP net income attributable to Merck & Co., Inc.					
Non-GAAP net income attributable to Merck & Co., Inc.					

Non-GAAP net income attributable to Merck & Co., Inc.	Non-GAAP net income attributable to Merck & Co., Inc.	\$ 5,427	\$ 4,703	\$ 3,771	\$ 14,876
EPS assuming dilution as reported under GAAP ⁽²⁾	EPS assuming dilution as reported under GAAP ⁽²⁾	\$ 1.86	\$ 1.28	\$ 0.62	\$ 4.53
EPS assuming dilution as reported under GAAP ⁽²⁾	EPS assuming dilution as reported under GAAP ⁽²⁾				
EPS difference	EPS difference				
EPS difference	EPS difference	0.27	0.57	0.86	1.33
Non-GAAP EPS assuming dilution ⁽²⁾	Non-GAAP EPS assuming dilution ⁽²⁾	\$ 2.13	\$ 1.85	\$ 1.48	\$ 5.86
Non-GAAP EPS assuming dilution ⁽²⁾	Non-GAAP EPS assuming dilution ⁽²⁾				

^(a) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.

^(b) GAAP and non-GAAP EPS were negatively affected in the first nine months quarter of 2024 and 2023 by \$4.52, \$0.26 per share and in both the third quarter and first nine months of 2022 by \$0.22, \$0.52 per share, respectively, of charges for certain upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions.

- 39 -

Acquisition- and Divestiture-Related Costs

Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets, and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.

Restructuring Costs

Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 54 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related

- 34 -

costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.

Income and Losses from Investments in Equity Securities

Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.

Certain Other Items

Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 107 to the condensed consolidated financial statements).

Research and Development Update

The Company currently has several candidates under regulatory review in the U.S. and internationally.

MK-1022, patritumab deruxtecan, a potential first-in-class HER3 directed DXd antibody drug conjugate (ADC), is under priority review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with two or more systemic therapies. The Biologics License Application (BLA) is based on the primary results from the HERTHENA-Lung01 pivotal Phase 2 trial and data results presented at the IASLC 2023 World Conference on Lung Cancer, which were simultaneously published in the Journal of Clinical Oncology. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 26, 2024 for the BLA. The priority review follows receipt of Breakthrough Therapy designation granted by the FDA in December 2021. The BLA is being reviewed under the Real-Time Oncology Review program. Patritumab deruxtecan (HER3-DXd) was discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck.

V116, the Company's investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults, is under priority review by the FDA. The BLA for V116 is supported by results from multiple Phase 3 clinical studies evaluating V116 in both vaccine-naïve and vaccine-experienced adult patient populations, including STRIDE-3, STRIDE-4, STRIDE-5 and STRIDE-6. The FDA set a PDUFA date of June 17, 2024. V116 was granted Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by *Streptococcus pneumoniae* serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is also under review in the EU.

MK-7962, *Winrevair* (sotatercept-csrk), Merck's novel activin signaling inhibitor, is under review in the EU for the treatment of adult patients with PAH (WHO Group 1). The application is based on the results from the Phase 3 STELLAR trial. *Winrevair* was granted Priority Medicines (PRIME) scheme and Orphan Drug designation by the European Medicines Agency for the treatment of PAH.

MK-7264, gefapixant, is an investigational, a non-narcotic, orally oral selective P2X3 receptor antagonist for the treatment of adults with refractory or unexplained chronic cough under review by the FDA. The marketing application for gefapixant is based on results from the COUGH-1 and COUGH-2 clinical trials, in adults. In September December 2023, the FDA announced it will hold issued a Pulmonary-Allergy Drugs Advisory Committee meeting on November 17, 2023 to discuss gefapixant. In January 2022, Merck received a second Complete Response Letter (CRL) for regarding the original NDA resubmission of Merck's New Drug Application for gefapixant. In the CRL, the FDA requested additional information related to concluded that Merck's application did not meet substantial evidence of effectiveness for treating refractory chronic cough counting system that was used to assess efficacy and unexplained chronic cough. The CRL was not related to the safety of gefapixant. In July 2023, Merck is reviewing the FDA accepted Merck's resubmission of the NDA for gefapixant and assigned a PDUFA date of December 27, 2023. In September 2023, the EC approved *Lyfhuia* (gefapixant), FDA's feedback to determine next steps.

MK-3475, *Keytruda*, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently encompasses studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.

Keytruda is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. *Keytruda* is approved for this indication in the U.S. under the FDA's accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.

Keytruda is also under priority review by the FDA in combination with external beam radiotherapy plus concurrent chemotherapy (carboplatin and paclitaxel), followed by brachytherapy (also known *Keytruda* as concurrent chemoradiotherapy) as a single agent for the treatment with definitive intent for newly diagnosed of patients with high-risk locally primary advanced cervical cancer. The submission is or recurrent endometrial carcinoma, based on the KEYNOTE-A18 KEYNOTE-868 trial. The FDA set a PDUFA date of January 20, 2024.

Additionally, *Keytruda* is under review by the FDA in combination with fluoropyrimidine- and platinum-containing chemotherapy June 21, 2024 for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. The submission is based on data from the KEYNOTE-859 trial. The FDA set a PDUFA date of December 16, 2023. KEYNOTE-859 supplemental BLA. KEYNOTE-868 is also under review in the EU and Japan. In October 2023, the CHMP of the EMA adopted a positive opinion recommending approval of *Keytruda* in combination with chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1. The CHMP's recommendation will now be reviewed by the EC for marketing authorization in the EU, and a final decision is expected in the fourth quarter of 2023.

- 40 -

In addition, *Keytruda* is under review in the EU and Japan in combination with standard of care chemotherapy (gemcitabine and cisplatin) Padcev (enfortumab vedotin-ejfv), an ADC, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer, urothelial carcinoma, based on data from the KEYNOTE-966 trial. KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer Inc.) and Astellas.

Keytruda is also under review in the EU and Japan in combination with chemoradiotherapy for the treatment of patients with high-risk locally advanced cervical cancer, based on the KEYNOTE-A18 trial.

Keytruda is under review in Japan as part of a perioperative treatment regimen for certain patients with resectable stage II, IIIA or IIIB NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant).

- 35 -

In September 2023, the FDA accepted and granted priority review for a supplemental NDA seeking approval for Additionally, *Welireg* for the treatment of adult patients with advanced RCC following immune checkpoint and anti-angiogenic therapies. The supplemental NDA is based on data from the LITESPARK-005 trial. The FDA set a PDUFA date of January 17, 2024.

Also in September 2023, the FDA accepted for priority review a Biologics License Application for sotatercept (MK-7962), Merck's novel investigational activin signaling inhibitor for the treatment of adult patients with PAH (World Health Organization Group 1). The application is based on the results from the Phase 3 STELLAR trial. The FDA set a PDUFA date of March 26, 2024. Merck has also submitted a marketing authorization application to the EMA. Sotatercept was granted Breakthrough Therapy Designation and Orphan Drug designation by the FDA, as well as Priority Medicines (PRIME) scheme and Orphan Drug designation by the EMA for the treatment of PAH. Sotatercept is the subject of a licensing agreement with BMS.

MK-4482, *Lagevrio*, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing *Lagevrio* in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for *Lagevrio* in December 2021, which was last reissued in February 2023. *Lagevrio* *Keytruda* is authorized for the treatment of adults with a current diagnosis of mild to moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVE-OUT trial. *Lagevrio* is not approved for any use under review in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food,

Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the EMA issued a positive scientific opinion for *Lagevrio*, which was intended to support national decision-making on the possible use of *Lagevrio* prior to marketing authorization. In October 2021, the EMA initiated a rolling review for *Lagevrio* for the treatment of COVID-19 in adults. In February 2023, Merck and Ridgeback announced that the CHMP of the EMA recommended the refusal of the marketing authorization application (MAA) for *Lagevrio*. Merck and Ridgeback appealed the decision and requested a re-examination of the MAA. In June 2023, Merck and Ridgeback announced that they have withdrawn the EU application for marketing authorization of *Lagevrio* based on the CHMP's view that the data submitted are not sufficient to satisfy EU regulatory requirements for marketing authorization of *Lagevrio*. Applications to other regulatory bodies are underway.

In July 2023, Merck and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy, Japan in combination with *Keytruda*, as an adjuvant treatment in patients with resected high-risk (Stage IIIB-IV) melanoma. The FDA fluoropyrimidine, and EMA granted Breakthrough Therapy Designation and PRIME scheme, respectively, for V940 (mRNA-4157) in combination with *Keytruda* platinum-containing chemotherapy for the adjuvant first-line treatment of patients with high-risk melanoma locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, based on data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, KEYNOTE-859 trial.

In August 2023, Merck announced the initiation of the Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment of adults with hypercholesterolemia. This *Keytruda* is the first Phase 3 clinical program for an oral PCSK9 inhibitor. The first participants have enrolled also under review in two registrational Phase 3 studies evaluating low-density lipoprotein (LDL) cholesterol reduction and a Phase 3 cardiovascular outcomes study.

In October 2023, Merck initiated a Phase 3 clinical trial for MK-7240 for the treatment of ulcerative colitis. MK-7240 is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. MK-7240, which was obtained as part of Merck's acquisition of Prometheus in June 2023, is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn's disease, and other autoimmune conditions.

Also in October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo's DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. Patritumab deruxtecan was granted Breakthrough Therapy Designation by the FDA in December 2021 standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with *epidermal growth factor receptor (EGFR)*-mutated locally advanced unresectable or metastatic NSCLC with disease progression biliary tract cancer, based on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. The submission of a BLA the KEYNOTE-966 trial.

Welireg is under review in the U.S. is planned by EU for the end treatment of March 2024 for patritumab deruxtecan, which is previously treated advanced RCC based on data from the HERTHENA-Lung01 Phase 2 trial. Ifinatamab deruxtecan is currently being evaluated as monotherapy in IDEate-01, a Phase 2 LITEPARK-005 clinical trial in patients with previously treated extensive-stage small-cell lung cancer (SCLC). Raludotatug deruxtecan is currently being evaluated in a first-in-human Phase 1 and for the treatment of VHL disease based on the LITESPARK-004 clinical trial. Designed using Daiichi Sankyo's proprietary DXd ADC technology to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor.

- 41 -

payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. See Note 3 to the condensed consolidated financial statements for additional information related to this collaboration.

The Company is in the process of discontinuing development of ladiratuzumab vedotin, an ADC targeting LIV-1, which was being developed in collaboration with Seagen Inc.

In August 2023, March 2024, Merck and Eisai provided an update on announced that in the Phase 3 LEAP-010 KEYLYNK-006 trial, evaluating *Keytruda* in combination with chemotherapy followed by *Keytruda* plus *Lenvima* as a first-line treatment for patients with recurrent or metastatic HNSCC whose tumors express PD-L1. Two planned interim analyses were conducted by an independent Data Monitoring Committee. In the first analysis, *Keytruda* plus *Lenvima* showed a statistically significant improvement in progression-free survival and objective response rate versus *Keytruda* plus placebo. At the second analysis, *Keytruda* plus *Lenvima* maintenance *Lynparza* did not demonstrate an improvement in meet the study's pre-specified statistical criteria for overall survival or progression-free survival compared to *Keytruda* in combination with chemotherapy (pemetrexed plus placebo). Accordingly, the study will be closed, and the companies informed investigators of this decision, carboplatin or cisplatin) followed by *Keytruda* plus maintenance chemotherapy (pemetrexed). A full evaluation of the data from this study including pre-planned subgroup analyses, is ongoing. The companies Merck will work with investigators to share the results with the scientific community.

In September 2023, Merck and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating *Keytruda* plus *Lenvima*. Also, the Company has discontinued development of MK-5475 in patients PAH but continues to study MK-5475 in PH associated with certain types of metastatic NSCLC. The LEAP-006 trial evaluating *Keytruda* plus *Lenvima* in combination with pemetrexed and platinum-containing chemotherapy versus *Keytruda* with pemetrexed and platinum-containing chemotherapy as a first-line treatment for adult patients with metastatic, nonsquamous NSCLC who have confirmation that *EGFR*-, *anaplastic lymphoma kinase (ALK)*- or *c-ros oncogene 1 (ROS1)*-directed therapies are not indicated, did not meet its dual primary endpoints of overall survival and progression free survival. The LEAP-008 trial evaluating *Keytruda* plus *Lenvima* versus docetaxel, a current second line standard of care option, as a treatment for patients with metastatic NSCLC who progressed on or after platinum-containing chemotherapy and one prior anti-PD-1/L1 immunotherapy, and have confirmation that *EGFR*-, *ALK*- or *ROS1*-directed therapies are not indicated, did not meet its dual primary endpoints of overall survival and progression free survival. The companies are working with investigators to share the results of both trials with the scientific community.

The charts chart below reflect reflects the Company's research pipeline as of November 1, 2023 May 1, 2024. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.

- 42 -

Phase 2		
<p>Cancer</p> <p>MK-1022 (pitratumab deruxtecan)⁽¹⁾ Gastric Melanoma</p> <p>MK-1308 (quavonilimab)⁽²⁾ Non-Small-Cell Lung</p> <p>MK-1308A (quavonilimab+pembrolizumab) Colorectal Small-Cell Lung</p> <p>MK-2140 (zilovertimab vedotin) Bladder Breast Gastric Hematological Malignancies Non-Small-Cell Lung Ovarian Pancreatic</p> <p>MK-2400 (ifinatimab deruxtecan)⁽¹⁾ Colorectal Small-Cell Lung</p> <p>MK-2870 (sacituzumab tirumotucan)⁽¹⁾⁽³⁾ Neoplasm Malignant</p> <p>MK-3475 Keytruda Advanced Solid Tumors Prostate</p> <p>MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Cutaneous Squamous Cell</p> <p>MK-3543 (bomedemstat) Myeloproliferative Disorders</p> <p>MK-4280 (favezelimab)⁽²⁾ Non-Small-Cell Lung</p> <p>MK-4280A (favezelimab+pembrolizumab) Bladder Cutaneous Squamous Cell Endometrial Esophageal Melanoma Renal Cell</p> <p>Small-Cell Lung</p> <p>MK-4830 MK-5890 (boserolimab)⁽²⁾ Colorectal Esophageal Melanoma Non-Small-Cell Lung Ovarian Renal Cell Small-Cell Lung</p> <p>Neoplasm Malignant</p>	<p>Cancer</p> <p>MK-5684 MK-5909 (raludotatug deruxtecan)⁽¹⁾ Prostate</p> <p>MK-5890 (boserolimab)⁽²⁾ Non-Small-Cell Lung Small-Cell Lung Ovarian</p> <p>MK-6482 Welreg⁽²⁾ Biliary Colorectal Endometrial Esophageal Hepatocellular Pancreatic Prostate Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU)</p> <p>MK-7119 Tukysa⁽²⁾ Advanced Solid Tumors Biliary Bladder Cervical Endometrial Gastric Non-Small-Cell Lung</p> <p>MK-7339 Lynparza⁽¹⁾⁽³⁾ Advanced Solid Tumors</p> <p>MK-7684A (vibostolimab+pembrolizumab) Biliary Bladder Breast Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hepatocellular Ovarian Prostate</p> <p>Renal</p> <p>V940⁽¹⁾⁽²⁾ Cutaneous Squamous Cell Bladder Renal Cell</p>	<p>Cancer</p> <p>MK-7902 Lenvima⁽¹⁾⁽²⁾ Biliary Head and Neck Pancreatic Prostate Small-Cell Lung</p> <p>Dengue Fever Virus Vaccine V181</p> <p>HIV-1 Infection</p> <p>MK-8591B (islatravir+MK-8507)⁽⁴⁾ MK-8591D (islatravir+lenacapavir)⁽¹⁾⁽⁵⁾</p> <p>HIV-1 Prevention</p> <p>MK-8527</p> <p>Nonalcoholic Steatohepatitis (NASH)</p> <p>MK-6024 (efinopagedutide)</p> <p>Pulmonary Arterial Hypertension Hypertension-Chronic Obstructive Pulmonary Disease</p> <p>MK-5475</p> <p>Pulmonary Hypertension Due To Left Heart Disease</p> <p>MK-7962 (sotatercept)Winrevair</p> <p>Schizophrenia</p> <p>MK-8189⁽⁶⁾</p> <p>Thrombosis</p> <p>MK-2060</p> <p>Vitiligo</p> <p>MK-6194</p>
		- 43 36 -

Phase 3 (Phase 3 entry date)			Under Review		
Antiviral COVID-19 MK-4482 <i>Lagevrio</i> (U.S.) (May 2021) Cancer MK-1022 (pembrolizumab+hyaluronidase subcutaneous) ⁽¹⁾ Non-Small-Cell Lung (May 2022) (EU) MK-1026 (nabirutinib) Hematological Malignancies (March 2023) MK-1308A (quaranolimab+pembrolizumab) Renal Cell (April 2021) MK-2870 (sacituzumab tirumotecan) ⁽¹⁾⁽²⁾ Breast (April 2024) Endometrial (December 2023) Non-Small-Cell Lung (November 2023) MK-3475 <i>Keytruda</i> Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-3543 (bomeđemstat) Myeloproliferative Disorders (December 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-6482 <i>Welireg</i> ⁽³⁾ Renal Cell (EU) (February 2020) MK-7119 <i>Tukysa</i> MK-5684 (opevesostat) ⁽¹⁾ Breast (October 2019) Colorectal (August 2022) Prostate (December 2023) MK-7339 <i>Lynparza</i> ⁽²⁾ Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Melanoma (January 2023) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 <i>Lenvima</i> ⁽¹⁾⁽²⁾ Esophageal (July 2021) Gastric (December 2020) V940 ⁽¹⁾⁽²⁾ Melanoma (July 2023) Non-Small-Cell Lung (December 2023) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) ⁽³⁾ Hypercholesterolemia MK-0616 (August 2023) Pneumococcal Vaccine Adult V116 (July 2022) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (EU) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) Ulcerative Colitis MK-7240 (tulisokibart) (October 2023)	New Molecular Entities Cancer MK-1022 (pembrolizumab deruxtecan) Non-Small-Cell Lung (U.S.) MK-6482 <i>Welireg</i> Von Hippel-Lindau (VHL) Disease (EU) Cough MK-7264 (gefapixant) (U.S.) Pneumococcal Vaccine Adult V116 (U.S.) (EU) Pulmonary Arterial Hypertension MK-7962 (sotatercept) U.S. <i>Winrevair</i> (EU)	Certain Supplemental Filings Cancer MK-3475 <i>Keytruda</i> <ul style="list-style-type: none"> Second-Line Hepatocellular Primary Advanced or Recurrent Endometrial Carcinoma (KEYNOTE-394) (KEYNOTE-868) (U.S.) (EU) (JPN) First-Line Locally Advanced or Metastatic Urothelial Cancer (KEYNOTE-A39) (EU) (JPN) High-Risk Locally Advanced Cervical Cancer (KEYNOTE-A18) (U.S.) (EU) (JPN) Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (JPN) First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KEYNOTE-859) (U.S.) (EU) (JPN) First-Line Locally Advanced Unresectable or Metastatic Biliary Tract Cancer (KEYNOTE-966) (EU) (JPN) Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (EU) (JPN) MK-6482 <i>Welireg</i> <ul style="list-style-type: none"> Previously Treated Advanced Renal Cell Carcinoma (LIGHTSPARK-005) (U.S.) (LITESPARK-005) (EU) 			
	Footnotes: <p>(1) Being developed in a collaboration.</p> <p>(2) Being developed in combination with <i>Keytruda</i>.</p> <p>(3) Being developed as monotherapy and/or in combination with <i>Keytruda</i>.</p> <p>(4) On FDA clinical hold.</p> <p>(5) On FDA partial clinical hold for higher doses than those used in current clinical trials.</p> <p>(6) Phase 2b development costs are being co-funded.</p> <p>(7) Available in the U.S. under Emergency Use Authorization.</p> <p>(8) In July December 2023, the FDA accepted Merck's resubmission of issued a CRL for the NDA for gefapixant following gefapixant. Merck is reviewing the Company's response FDA's feedback to the CRL received in January 2022, determine next steps.</p>	March 31, 2024	December 31, 2023		

Analysis of Liquidity and Capital Resources

	(\$ in millions)	(\$ in millions)	September 30, 2023	December 31, 2022	(\$ in millions)	March 31, 2024	December 31, 2023
Cash and investments	Cash and investments	\$ 10,079	\$ 14,207				
Working capital	Working capital	8,860	11,483				
Total debt to total liabilities and equity	Total debt to total liabilities and equity						
32.7 %	28.1 %				32.3 %	32.9 %	

Cash provided by operating activities was \$12.8 billion \$3.1 billion in the first nine three months of 2024 compared with \$1.3 billion in the first three months of 2023 compared with \$14.7 billion in the first nine months of 2022. Cash provided by reflecting stronger operating activities in the first nine months of 2023 was reduced by payments of \$567 million related to the previously disclosed Zetia antitrust settlement of \$572.5 million. Cash provided by operating activities was reduced by milestone and option payments related to certain collaborations of \$240 million \$245 million and \$2.0 billion \$115 million in the first nine three months of 2023 2024 and 2022, 2023, respectively. Cash provided by operating activities continues to be the Company's primary source of funds to finance operating needs, with excess cash generally serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.

Cash used in investing activities was \$14.1 billion \$1.4 billion in the first nine three months of 2023 2024 compared with \$3.2 billion \$2.4 billion in the first nine three months of 2022, 2023. The higher lower use of cash in investing activities was primarily due to the lower cash used for acquisitions, lower purchases of Prometheus securities and *Imago*, other investments, as well as lower capital expenditures, partially offset by higher proceeds from sales of securities and other investments, as well as lower capital expenditures, investments.

Cash used in financing activities was \$2.6 billion \$2.8 billion in the first **nine** three months of **2023** **2024** compared with \$7.6 billion \$2.1 billion in the first **nine** three months of **2022**, **2023**. The **change** **higher** use of cash in financing activities was primarily due to **proceeds from the issuance of debt** (see below) and **lower** **higher** payments on **long-term debt** (see below), partially offset by **treasury stock purchases** and higher dividends paid to **shareholders**, partially offset by higher proceeds from the exercise of stock options and lower purchases of treasury stock.

- 44 37 -

The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored \$3.5 billion \$2.7 billion and \$2.5 billion \$3.0 billion of accounts receivable at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.

In May 2023, the Company issued \$6.0 billion principal amount of senior unsecured notes consisting of \$500 million of 4.05% notes due 2028, \$750 million of 4.30% notes due 2030, \$1.5 billion of 4.50% notes due 2033, \$750 million of 4.90% notes due 2044, \$1.5 billion of 5.00% notes due 2053, and \$1.0 billion of 5.15% notes due 2063. The Company used a portion of the \$5.9 billion net proceeds from this offering to fund a portion of the cash consideration paid for the acquisition of Prometheus, including related fees and expenses, and used the remaining net proceeds for general corporate purposes including to repay commercial paper borrowings and other indebtedness with upcoming maturities.

In May 2023, March 2024, the Company's \$1.75 billion \$750 million, 2.80% notes matured in accordance with their terms and were repaid. In February 2022, the Company's \$1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company's \$1.0 billion, 2.40% 2.90% notes matured in accordance with their terms and were repaid.

Dividends paid to stockholders were \$5.6 billion \$2.0 billion and \$5.3 billion \$1.9 billion for the first **nine** three months of **2023** **2024** and **2022**, **2023**, respectively. In May November 2023, Merck's Board of Directors declared a quarterly dividend of \$0.77 per share on the Company's outstanding common stock for the first quarter of 2024 that was paid in January 2024. In January 2024, the Board of Directors declared a quarterly dividend of \$0.73 \$0.77 per share on the Company's outstanding common stock for the second quarter that was paid in July 2023. In July 2023, the Board of Directors declared a quarterly dividend of \$0.73 per share on the Company's outstanding common stock for the third quarter that was paid in October 2023, April 2024.

In 2018, Merck's Board of Directors authorized purchases of up to \$10 billion of Merck's common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company has made and anticipates continuing to make modest share repurchases under this program in 2023. During the first **nine** three months of **2023**, **2024**, the Company purchased \$953 million (\$122 million 1 million shares) of its common stock for its treasury under this program. As of **September 30, 2023** **March 31, 2024**, the Company's remaining share repurchase authorization was \$4.1 \$3.6 billion.

The Company has a \$6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company's commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.

Critical Accounting Estimates

The Company's significant accounting policies, which include management's best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended **December 31, 2022** **December 31, 2023** included in Merck's Form 10-K filed on **February 24, 2023** **February 26, 2024**. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management's Discussion and Analysis of Financial Condition and Results of Operations included in Merck's Form 10-K. There have been no significant changes in the Company's critical accounting estimates since **December 31, 2022** **December 31, 2023**.

Recently Issued Accounting Standards

For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes in market risk exposures that affect the disclosures presented in "Item 7A. Quantitative and Qualitative Disclosures about Market Risk" in the Company's **2022** **2023** Form 10-K filed on **February 24, 2023** **February 26, 2024**.

Item 4. Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures over financial reporting. Based on their evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that as of **September 30, 2023** **March 31, 2024**, the Company's disclosure controls and procedures are effective. For the **third** **first** quarter of **2023**, **2024**, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

This report and other written reports and oral statements made from time to time by the Company may contain so-called "forward-looking statements," all of which are based on management's current expectations and are subject to risks and

- 45 -

uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as "anticipates," "expects," "plans," "will," "estimates," "forecasts," "projects" and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company's growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company's filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, filed on February 24, 2023 February 26, 2024, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.

PART II - Other Information

Item 1. Legal Proceedings

The information called for by this Item is incorporated herein by reference to Note 107 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer purchases of equity securities for the three months ended September 30, 2023 March 31, 2024 were as follows:

ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased (1)	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares	
				Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(\$ in millions)
July January 1 - July January 31	147,500	1,918,488	\$112.29	147,500	\$108.79 1,918,488 \$4,351 3,684
August February 1 - August 31	209,200	1,450,550	\$127.83	209,200	\$106.99 1,450,550 \$4,196 3,658
September March 1 - September 30	633,971	950,239	\$123.45	633,971	\$107.33 950,239 \$4,094 3,579
Total	4,319,277	990,671		\$107.86 122.71	4,319,277 990,671

(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to \$10 billion of Merck's common stock for its treasury.

Item 5. Other Information

Insider Trading Arrangements

During the three months ended September 30, 2023 March 31, 2024, none of the Company's directors or executive officers adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.

- 46 39 -

Item 6. Exhibits

<u>Number</u>	<u>Description</u>
3.1	— Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November 4, 2009 (No. 1-6571)
3.2	— By-Laws of Merck & Co., Inc. (effective March 22, 2022) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)
31.1	— Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer
31.2	— Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer
32.1	— Section 1350 Certification of Chief Executive Officer
32.2	— Section 1350 Certification of Chief Financial Officer
101.INS	— XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	— XBRL Taxonomy Extension Schema Document.
101.CAL	— XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	— XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	— XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	— XBRL Taxonomy Extension Presentation Linkbase Document.
104	— Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

- 47 40 -

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MERCK & CO., INC.

Date: November 3, 2023 May 3, 2024

/s/ Jennifer Zachary

JENNIFER ZACHARY

Executive Vice President and General Counsel

Date: November 3, 2023 May 3, 2024

/s/ Rita A. Karachun Dalton Smart

RITA A. KARACHUNDALTON SMART

Senior Vice President Finance - Global Controller

- 48 41 -

Exhibit 31.1

CERTIFICATION

I, Robert M. Davis, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2023 May 3, 2024

By: /s/ Robert M. Davis
 ROBERT M. DAVIS
 Chairman, and Chief Executive Officer and President

Exhibit 31.2

CERTIFICATION

I, Caroline Litchfield, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the

registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 3, 2023** May 3, 2024

By: /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

Exhibit 32.1

Section 1350
Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the "Company"), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended **September 30, 2023** March 31, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **November 3, 2023** May 3, 2024

/s/ Robert M. Davis
Name: ROBERT M. DAVIS
Title: Chairman, and Chief Executive Officer and President

Exhibit 32.2

Section 1350
Certification of Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the "Company"), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended **September 30, 2023** March 31, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: **November 3, 2023** May 3, 2024

/s/ Caroline Litchfield
Name: CAROLINE LITCHFIELD
Title: Executive Vice President, Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.